The	O
sodium	B-GP
channel	I-GP
β1	I-GP
subunit	O
mediates	O
outgrowth	O
of	O
neurite	O
-	O
like	O
processes	O
on	O
breast	B-DS
cancer	I-DS
cells	O
and	O
promotes	O
tumour	B-DS
growth	O
and	O
metastasis	O

Grant	O
sponsor	O
:	O
Medical	O
Research	O
Council	O
;	O
Grant	O
number	O
:	O
G1000508	O

Voltage	B-GP
-	I-GP
gated	I-GP
Na	I-GP
+	I-GP
channels	I-GP
(	O
VGSCs	B-GP
)	O
are	O
heteromeric	O
proteins	O
composed	O
of	O
pore	O
-	O
forming	O
α	O
subunits	O
and	O
smaller	O
β	O
subunits	O
.	O

The	O
β	O
subunits	O
are	O
multifunctional	O
channel	O
modulators	O
and	O
are	O
members	O
of	O
the	O
immunoglobulin	B-GP
superfamily	O
of	O
cell	B-GP
adhesion	I-GP
molecules	I-GP
(	O
CAMs	B-GP
).	O
β1	O
,	O
encoded	O
by	O
SCN1B	B-GP
,	O
is	O
best	O
characterized	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
),	O
where	O
it	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
electrical	O
excitability	O
,	O
neurite	O
outgrowth	O
and	O
migration	O
during	O
development	O
.	O
β1	O
is	O
also	O
expressed	O
in	O
breast	B-DS
cancer	I-DS
(	O
BCa	B-DS
)	O
cell	O
lines	O
,	O
where	O
it	O
regulates	O
adhesion	O
and	O
migration	O
in	O
vitro	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
SCN1B	B-GP
mRNA	O
/	O
β1	O
protein	O
were	O
up	O
-	O
regulated	O
in	O
BCa	B-DS
specimens	O
,	O
compared	O
with	O
normal	O
breast	O
tissue	O
.	O
β1	O
upregulation	O
substantially	O
increased	O
tumour	B-DS
growth	O
and	O
metastasis	O
in	O
a	O
xenograft	O
model	O
of	O
BCa	B-DS
.	O
β1	O
over	O
-	O
expression	O
also	O
increased	O
vascularization	O
and	O
reduced	O
apoptosis	O
in	O
the	O
primary	O
tumours	B-DS
,	O
and	O
β1	O
over	O
-	O
expressing	O
tumour	B-DS
cells	O
had	O
an	O
elongate	O
morphology	O
.	O
In	O
vitro	O
,	O
β1	O
potentiated	O
outgrowth	O
of	O
processes	O
from	O
BCa	B-DS
cells	O
co	O
-	O
cultured	O
with	O
fibroblasts	O
,	O
via	O
trans	O
-	O
homophilic	O
adhesion	O
.	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
in	O
BCa	B-DS
cells	O
required	O
the	O
presence	O
and	O
activity	O
of	O
fyn	B-GP
kinase	I-GP
,	O
and	O
Na	O
+	O
current	O
,	O
thus	O
replicating	O
the	O
mechanism	O
by	O
which	O
β1	O
regulates	O
neurite	O
outgrowth	O
in	O
CNS	O
neurons	O
.	O

We	O
conclude	O
that	O
when	O
present	O
in	O
breast	B-DS
tumours	I-DS
,	O
β1	O
enhances	O
pathological	O
growth	O
and	O
cellular	O
dissemination	O
.	O

This	O
study	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
functional	O
role	O
for	O
β1	O
in	O
tumour	B-DS
growth	O
and	O
metastasis	O
in	O
vivo	O
.	O

We	O
propose	O
that	O
β1	O
warrants	O
further	O
study	O
as	O
a	O
potential	O
biomarker	O
and	O
targeting	O
β1	O
-	O
mediated	O
adhesion	O
interactions	O
may	O
have	O
value	O
as	O
a	O
novel	O
anti	O
-	O
cancer	B-DS
therapy	O
.	O

Although	O
the	O
death	O
rate	O
from	O
breast	B-DS
cancer	I-DS
(	O
BCa	B-DS
)	O
is	O
falling	O
in	O
many	O
countries	O
,	O
it	O
is	O
still	O
the	O
leading	O
cause	O
of	O
cancer	B-DS
-	O
related	O
deaths	O
in	O
women	O
,	O
due	O
to	O
metastasis	O
.	O
1	O
,	O
2	O
To	O
metastasize	O
,	O
tumour	B-DS
cells	O
undergo	O
a	O
complex	O
sequence	O
of	O
events	O
,	O
including	O
adhesion	O
/	O
detachment	O
,	O
migration	O
,	O
and	O
invasion	O
.	O

Given	O
that	O
treatment	O
options	O
for	O
metastatic	O
BCa	B-DS
are	O
mainly	O
restricted	O
to	O
palliation	O
,	O
it	O
is	O
necessary	O
to	O
better	O
understand	O
the	O
mechanism	O
(	O
s	O
)	O
involved	O
in	O
order	O
to	O
identify	O
new	O
targets	O
and	O
develop	O
new	O
therapies	O
.	O
3	O

Voltage	B-GP
-	I-GP
gated	I-GP
Na	I-GP
+	I-GP
channels	I-GP
(	O
VGSCs	B-GP
)	O
contain	O
one	O
pore	O
-	O
forming	O
α	O
subunit	O
with	O
smaller	O
β	O
subunits	O
.	O
4	O
There	O
are	O
nine	O
α	O
subunits	O
,	O
Nav1	B-GP
.	I-GP
1	I-GP
-	O
Nav1	B-GP
.	I-GP
9	I-GP
,	O
and	O
four	O
β	O
subunits	O
,	O
β1	O
-	O
β4	O
.	O

The	O
β	O
subunits	O
are	O
members	O
of	O
the	O
immunoglobulin	B-GP
superfamily	O
of	O
cell	B-GP
adhesion	I-GP
molecules	I-GP
(	O
CAMs	B-GP
).	O

They	O
modulate	O
channel	O
gating	O
,	O
and	O
can	O
function	O
as	O
CAMs	B-GP
both	O
in	O
the	O
presence	O
and	O
absence	O
of	O
α	O
subunits	O
.	O
5	O
They	O
are	O
substrates	O
for	O
secretase	B-GP
cleavage	O
,	O
releasing	O
soluble	O
intracellular	O
domains	O
that	O
may	O
regulate	O
gene	O
expression	O
.	O
6	O
The	O
β1	O
subunit	O
(	O
gene	O
:	O
SCN1B	B-GP
)	O
participates	O
in	O
trans	O
-	O
homophilic	O
adhesion	O
,	O
resulting	O
in	O
cellular	O
aggregation	O
and	O
cytoskeleton	O
recruitment	O
.	O
7	O
,	O
8	O
β1	O
also	O
interacts	O
heterophilically	O
with	O
other	O
CAMs	B-GP
,	O
including	O
β2	O
,	O
contactin	B-GP
,	O
neurofascins	B-GP
,	O
NrCAM	B-GP
,	O
N	B-GP
-	I-GP
cadherin9	I-GP
–	O
12	O
and	O
the	O
extracellular	B-GP
matrix	I-GP
protein	I-GP
,	O
tenascin	B-GP
-	I-GP
R	I-GP
.	O
13	O
β1	O
mediates	O
neurite	O
outgrowth	O
by	O
a	O
trans	O
-	O
homophilic	O
adhesion	O
mechanism	O
that	O
requires	O
fyn	B-GP
kinase	I-GP
,	O
contactin	B-GP
and	O
γ	B-GP
-	I-GP
secretase	I-GP
activity	O
.	O
5	O
,	O
14	O
,	O
15	O
β1	O
plays	O
a	O
critical	O
role	O
during	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
development	O
,	O
regulating	O
electrical	O
excitability	O
,	O
proliferation	O
,	O
fasciculation	O
,	O
pathfinding	O
and	O
migration	O
.	O
15	O
–	O
17	O

VGSCs	B-GP
are	O
widely	O
expressed	O
in	O
cancers	B-DS
,	O
and	O
contribute	O
to	O
cellular	O
behaviours	O
associated	O
with	O
metastasis	O
.	O
18	O
,	O
19	O
In	O
BCa	B-DS
,	O
the	O
predominant	O
α	O
subunit	O
,	O
Nav1	B-GP
.	I-GP
5	I-GP
(	O
gene	O
:	O
SCN5A	B-GP
),	O
is	O
expressed	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
,	O
where	O
Na	O
+	O
current	O
potentiates	O
invasion	O
by	O
enhancing	O
cysteine	B-GP
cathepsin	I-GP
activity	O
.	O
20	O
–	O
22	O
SCN5A	B-GP
is	O
up	O
-	O
regulated	O
in	O
tumours	B-DS
,	O
associating	O
with	O
recurrence	O
,	O
metastasis	O
and	O
reduced	O
survival	O
.	O
20	O
,	O
23	O
β1	O
is	O
the	O
predominant	O
β	O
subunit	O
in	O
MCF	O
-	O
7	O
cells	O
,	O
where	O
it	O
enhances	O
cell	O
-	O
substrate	O
adhesion	O
,	O
but	O
slows	O
transwell	O
migration	O
.	O
24	O
Over	O
-	O
expression	O
of	O
β1	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
increases	O
cell	O
-	O
cell	O
adhesion	O
and	O
Na	O
+	O
current	O
.	O
24	O
Both	O
α	O
and	O
β1	O
subunits	O
are	O
expressed	O
in	O
lamellipodia	O
of	O
MCF	O
-	O
7	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
,	O
suggesting	O
that	O
their	O
expression	O
and	O
function	O
are	O
not	O
mutually	O
exclusive	O
.	O
23	O
Thus	O
,	O
VGSC	B-GP
α	I-GP
and	O
β	O
subunits	O
appear	O
to	O
play	O
complex	O
,	O
dynamic	O
roles	O
in	O
metastatic	O
BCa	B-DS
cells	O
.	O

However	O
,	O
the	O
functional	O
significance	O
of	O
β1	O
-	O
dependent	O
adhesion	O
,	O
and	O
its	O
contribution	O
to	O
tumour	B-DS
growth	O
and	O
metastasis	O
,	O
are	O
unknown	O
.	O

Our	O
aim	O
here	O
was	O
to	O
study	O
the	O
involvement	O
of	O
β1	O
in	O
BCa	B-DS
progression	O
in	O
vivo	O
.	O

We	O
show	O
that	O
SCN1B	B-GP
mRNA	O
/	O
β1	O
protein	O
are	O
upregulated	O
in	O
BCa	B-DS
specimens	O
,	O
compared	O
with	O
normal	O
breast	O
tissue	O
.	O

Up	O
-	O
regulation	O
of	O
β1	O
potentiates	O
tumour	B-DS
growth	O
and	O
metastasis	O
in	O
vivo	O
.	O

In	O
addition	O
,	O
β1	O
increases	O
process	O
outgrowth	O
on	O
BCa	B-DS
cells	O
via	O
a	O
trans	O
-	O
homophilic	O
adhesion	O
mechanism	O
that	O
requires	O
fyn	B-GP
kinase	I-GP
and	O
Na	O
+	O
current	O
.	O

We	O
propose	O
that	O
β1	O
enhances	O
metastatic	O
behaviour	O
of	O
BCa	B-DS
cells	O
by	O
recapitulating	O
mechanism	O
(	O
s	O
)	O
that	O
are	O
critical	O
for	O
neuronal	O
migration	O
during	O
CNS	O
development	O
.	O

These	O
findings	O
suggest	O
that	O
β1	O
warrants	O
further	O
study	O
as	O
a	O
potential	O
biomarker	O
/	O
therapeutic	O
target	O
.	O

Methods	O

In	O
silico	O
analysis	O

SCN1B	B-GP
expression	O
in	O
microarrays	O
was	O
studied	O
using	O
Oncomine	O
.	O
25	O
Meta	O
-	O
analysis	O
of	O
correlations	O
between	O
SCN1B	B-GP
expression	O
and	O
histoclinical	O
characteristics	O
across	O
multiple	O
datasets	O
was	O
as	O
described	O
.	O
26	O
Datasets	O
,	O
patients	O
,	O
specimen	O
characteristics	O
and	O
assay	O
methods	O
are	O
detailed	O
/	O
referenced	O
at	O
http	O
://	O
www	O
.	O
oncomine	O
.	O
org	O
.	O

Cell	O
culture	O

Molecular	O
identity	O
of	O
all	O
BCa	B-DS
cell	O
lines	O
was	O
confirmed	O
by	O
short	O
tandem	O
repeat	O
analysis	O
.	O

All	O
cell	O
lines	O
were	O
grown	O
in	O
Dulbecco	O
'	O
s	O
modified	O
eagle	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
5	O
%	O
fetal	O
bovine	O
serum	O
and	O
4	O
mM	O
l	O
-	O
glutamine	O
.	O
23	O
BT474	O
and	O
SKBR3	O
cells	O
were	O
a	O
gift	O
from	O
J	O
.	O

Rae	O
,	O
University	O
of	O
Michigan	O
.	O

MCF	O
-	O
7	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
were	O
a	O
gift	O
from	O
M	O
.	O

Djamgoz	O
,	O
Imperial	O
College	O
London	O
.	O
“	O
Control	O
”	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
stably	O
expressing	O
enhanced	O
green	B-GP
fluorescent	I-GP
protein	I-GP
(	O
GFP	B-GP
)	O
or	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
over	O
-	O
expressing	O
β1	O
-	O
GFP	B-GP
C	O
-	O
terminal	O
fusion24	O
(	O
hereafter	O
called	O
“	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
”	O
cells	O
)	O
were	O
maintained	O
in	O
medium	O
containing	O
selective	O
antibiotics	O
.	O

MCF	O
-	O
10A	O
cells	O
were	O
a	O
gift	O
from	O
N	O
.	O

Maitland	O
,	O
University	O
of	O
York	O
.	O

R1610	O
Chinese	B-OG
hamster	I-OG
lung	O
(	O
CHL	O
)	O
fibroblasts	O
and	O
CHL	O
fibroblasts	O
stably	O
expressing	O
β1	O
were	O
gifts	O
from	O
L	O
.	O

Isom	O
,	O
University	O
of	O
Michigan	O
.	O

MDA	O
-	O
MB	O
-	O
231	O
-	O
GFP	B-GP
and	O
MDA	O
-	O
MB	O
-	O
231	O
β1	O
-	O
GFP	B-GP
cells	O
were	O
stably	O
transduced	O
with	O
recombinant	O
lentivirus	B-OG
for	O
firefly	B-OG
luciferase	B-GP
(	O
AMS	O
Biotechnology	O
).	O

For	O
experiments	O
using	O
estrogen	O
,	O
MCF	O
-	O
7	O
cells	O
were	O
maintained	O
in	O
phenol	O
red	O
-	O
free	O
DMEM	O
supplemented	O
with	O
5	O
%	O
charcoal	O
-	O
stripped	O
fetal	O
bovine	O
serum	O
and	O
4	O
mM	O
L	O
-	O
glutamine	O
.	O

Cells	O
were	O
confirmed	O
as	O
mycoplasma	B-OG
-	O
free	O
using	O
the	O
DAPI	O
method	O
.	O

Pharmacology	O

Tetrodotoxin	O
(	O
TTX	O
)	O
was	O
diluted	O
in	O
culture	O
medium	O
to	O
30	O
µM	O
.	O

Staurosporine	O
,	O
PP2	O
,	O
estradiol	O
and	O
fulvestrant	O
were	O
prepared	O
as	O
stocks	O
in	O
DMSO	O
and	O
then	O
diluted	O
in	O
culture	O
medium	O
to	O
10	O
nM	O
−	O
30	O
µM	O
.	O

In	O
assays	O
that	O
exceeded	O
24	O
h	O
,	O
treatments	O
were	O
replaced	O
daily	O
.	O

The	O
effect	O
of	O
TTX	O
on	O
invasion	O
was	O
determined	O
using	O
Matrigel	O
assays	O
.	O
23	O
The	O
effect	O
of	O
staurosporine	O
on	O
apoptosis	O
was	O
determined	O
using	O
DeadEnd	O
fluorometric	O
TUNEL	O
assays	O
(	O
Promega	O
).	O

The	O
effect	O
of	O
PP2	O
on	O
cell	O
viability	O
and	O
proliferation	O
was	O
determined	O
using	O
trypan	O
blue	O
and	O
MTT	O
assays	O
.	O
23	O

RNA	O
isolation	O
and	O
RT	O
-	O
qPCR	O

RNA	O
extraction	O
and	O
cDNA	O
synthesis	O
were	O
as	O
described	O
.	O
27	O
QPCR	O
was	O
carried	O
out	O
using	O
triplicate	O
12	O
-	O
µl	O
reactions	O
containing	O
20ng	O
cDNA	O
.	O

Amplification	O
conditions	O
were	O
:	O
95	O
°	O
C	O
for	O
30	O
s	O
followed	O
by	O
35	O
cycles	O
of	O
95	O
°	O
C	O
for	O
5	O
s	O
and	O
60	O
°	O
C	O
for	O
10	O
s	O
on	O
a	O
Bio	O
-	O
Rad	O
thermal	O
cycler	O
.	O

Relative	O
gene	O
expression	O
was	O
quantitated	O
using	O
the	O
comparative	O
CT	O
method	O
.	O

Primers	O
are	O
in	O
Supporting	O
Information	O
Table	O
S1	O
.	O

Patient	O
tissue	O
samples	O

The	O
study	O
cohort	O
contained	O
tissue	O
samples	O
from	O
66	O
BCa	B-DS
cases	O
obtained	O
from	O
the	O
Breast	B-DS
Cancer	I-DS
Campaign	O
Tissue	O
Bank	O
under	O
tissue	O
request	O
number	O
TR000017	O
.	O

Patients	O
provided	O
consent	O
to	O
the	O
Breast	B-DS
Cancer	I-DS
Campaign	O
Tissue	O
Bank	O
for	O
their	O
tissues	O
to	O
be	O
used	O
for	O
research	O
.	O

The	O
samples	O
came	O
from	O
women	O
aged	O
28	O
–	O
89	O
years	O
,	O
who	O
were	O
diagnosed	O
between	O
February	O
1992	O
and	O
February	O
2012	O
.	O

For	O
40	O
cases	O
(	O
60	O
%),	O
tumour	B-DS
samples	O
came	O
with	O
matched	O
surrounding	O
normal	O
breast	O
tissue	O
.	O

Clinical	O
and	O
histopathological	O
data	O
were	O
available	O
for	O
all	O
cases	O
.	O

Immunohistochemistry	O
was	O
performed	O
on	O
5µm	O
-	O
thick	O
sections	O
using	O
the	O
EnVision	O
+	O
System	O
-	O
HRP	O
kit	O
(	O
Dako	O
).	O

Sections	O
were	O
deparaffinized	O
in	O
Histo	O
-	O
Clear	O
(	O
National	O
Diagnostics	O
)	O
followed	O
by	O
antigen	O
retrieval	O
at	O
95	O
°	O
C	O
for	O
30	O
min	O
in	O
Target	O
Retrieval	O
Solution	O
(	O
Dako	O
).	O

Sections	O
were	O
incubated	O
with	O
anti	O
-	O
β1	O
antibody	O
(	O
1	O
:	O
25	O
;	O
Abgent	O
)	O
for	O
30	O
mins	O
and	O
counterstained	O
with	O
dilute	O
Mayer	O
'	O
s	O
hematoxylin	O
and	O
mounted	O
in	O
Faramount	O
medium	O
(	O
Dako	O
).	O

Slides	O
were	O
scanned	O
at	O
40	O
×	O
using	O
an	O
Aperio	O
ScanScope	O
.	O
β1	O
immunoreactivity	O
was	O
scored	O
by	O
two	O
independent	O
investigators	O
(	O
WJB	O
and	O
RMS	O
,	O
a	O
breast	O
histopathologist	O
)	O
using	O
the	O
Allred	O
method	O
.	O
28	O
Briefly	O
,	O
the	O
proportion	O
of	O
β1	O
-	O
positive	O
cells	O
was	O
given	O
a	O
score	O
(	O
none	O
:	O
0	O
;	O
<	O
1	O
/	O
100	O
:	O
1	O
;	O
1	O
/	O
100	O
to	O
1	O
/	O
10	O
:	O
2	O
;	O
1	O
/	O
10	O
to	O
1	O
/	O
3	O
:	O
3	O
;	O
1	O
/	O
3	O
to	O
2	O
/	O
3	O
:	O
4	O
;	O
>	O
2	O
/	O
3	O
:	O
5	O
),	O
followed	O
by	O
the	O
intensity	O
of	O
staining	O
(	O
none	O
:	O
0	O
;	O
weak	O
:	O
1	O
;	O
intermediate	O
:	O
2	O
;	O
strong	O
:	O
3	O
).	O

For	O
each	O
section	O
,	O
the	O
proportion	O
and	O
intensity	O
scores	O
were	O
summed	O
to	O
give	O
a	O
total	O
score	O
(	O
0	O
–	O
8	O
).	O

A	O
score	O
of	O
0	O
–	O
4	O
was	O
considered	O
“	O
low	O
”	O
and	O
5	O
–	O
8	O
was	O
considered	O
“	O
high	O
.”	O
Scoring	O
was	O
performed	O
without	O
prior	O
knowledge	O
of	O
outcome	O
data	O
.	O

Experiments	O
were	O
approved	O
by	O
the	O
University	O
of	O
York	O
Ethical	O
Review	O
Process	O
.	O

Western	O
blotting	O

SDS	O
-	O
PAGE	O
was	O
performed	O
as	O
described	O
.	O
15	O
,	O
29	O
The	O
following	O
antibodies	O
were	O
used	O
:	O
rabbit	B-OG
anti	O
-	O
β1	O
(	O
1	O
:	O
100	O
;	O
Abgent	O
),	O
mouse	B-OG
anti	O
-	O
fyn	B-GP
(	O
1	O
:	O
1	O
,	O
000	O
;	O
BioLegend	O
),	O
mouse	B-OG
anti	O
-	O
CD44	B-GP
(	O
1	O
:	O
1	O
,	O
000	O
;	O
AbD	O
Serotec	O
);	O
rabbit	B-OG
anti	O
-	O
E	B-GP
-	I-GP
cadherin	I-GP
(	O
1	O
:	O
1	O
,	O
000	O
;	O
Cell	O
Signaling	O
Technology	O
);	O
mouse	B-OG
anti	O
-	O
β	B-GP
-	I-GP
actin	I-GP
(	O
1	O
:	O
30	O
,	O
000	O
;	O
Proteintech	O
);	O
and	O
mouse	B-OG
anti	O
-	O
α	B-GP
-	I-GP
tubulin	I-GP
(	O
1	O
:	O
10	O
,	O
000	O
;	O
Sigma	O
).	O

Signals	O
were	O
quantified	O
using	O
ImageJ	O
software	O
.	O
α	B-GP
-	I-GP
tubulin	I-GP
was	O
used	O
as	O
loading	O
control	O
.	O

Orthotopic	O
breast	B-DS
tumour	I-DS
model	O

All	O
animal	O
procedures	O
were	O
carried	O
out	O
after	O
approval	O
by	O
the	O
University	O
of	O
York	O
Ethical	O
Review	O
Process	O
and	O
under	O
authority	O
of	O
a	O
UK	O
Home	O
Office	O
Project	O
Licence	O
.	O

Six	O
-	O
week	O
-	O
old	O
female	O
Rag2	B-GP
−/−	O
Il2rg	B-GP
−/−	O
mice	B-OG
(	O
mean	O
weight	O
:	O
16	O
.	O
6	O
±	O
0	O
.	O
2	O
g	O
)	O
were	O
obtained	O
from	O
the	O
Yorkshire	O
Cancer	B-DS
Research	O
Unit	O
,	O
University	O
of	O
York	O
.	O

Mice	B-OG
(	O
4	O
–	O
5	O
per	O
specific	O
pathogen	O
free	O
cage	O
)	O
were	O
selected	O
at	O
random	O
for	O
surgery	O
.	O

A	O
1	O
×	O
106	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
GFP	B-GP
or	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
-	O
GFP	B-GP
cells	O
expressing	O
luciferase	B-GP
were	O
suspended	O
in	O
Matrigel	O
(	O
20	O
%	O
v	O
/	O
v	O
in	O
saline	O
)	O
and	O
injected	O
into	O
the	O
left	O
and	O
right	O
inguinal	O
mammary	O
fat	O
pad	O
of	O
each	O
animal	O
whilst	O
under	O
isoflurane	O
anaesthesia	O
.	O

A	O
total	O
of	O
13	O
mice	B-OG
were	O
used	O
(	O
six	O
injected	O
with	O
control	O
cells	O
and	O
seven	O
with	O
β1	O
cells	O
)	O
across	O
three	O
independent	O
replicated	O
experiments	O
.	O

Tumour	B-DS
growth	O
was	O
monitored	O
weekly	O
by	O
bioluminescence	O
imaging	O
.	O

Mice	B-OG
were	O
given	O
intraperitoneal	O
injection	O
of	O
D	O
-	O
luciferin	O
in	O
PBS	O
(	O
150	O
mg	O
kg	O
−	O
1	O
)	O
and	O
bioluminescence	O
was	O
visualized	O
10	O
min	O
later	O
under	O
isoflurane	O
anaesthesia	O
using	O
an	O
IVIS100	O
system	O
(	O
PerkinElmer	O
).	O

Bioluminescence	O
from	O
tumours	B-DS
was	O
quantified	O
within	O
manually	O
defined	O
regions	O
of	O
interest	O
using	O
Living	O
Image	O
software	O
(	O
PerkinElmer	O
)	O
and	O
expressed	O
as	O
photon	O
flux	O
.	O

To	O
quantify	O
bioluminescence	O
at	O
sites	O
of	O
metastasis	O
,	O
mice	B-OG
were	O
euthanized	O
∼	O
10	O
min	O
after	O
injection	O
with	O
D	O
-	O
luciferin	O
,	O
primary	O
tumours	B-DS
were	O
removed	O
and	O
internal	O
organs	O
were	O
exposed	O
by	O
dissection	O
.	O

Bioluminescence	O
was	O
measured	O
from	O
the	O
entire	O
mouse	B-OG
and	O
then	O
individual	O
organs	O
were	O
removed	O
for	O
separate	O
imaging	O
.	O

Measurements	O
of	O
the	O
length	O
and	O
width	O
of	O
each	O
tumour	B-DS
(	O
in	O
mm	O
)	O
were	O
taken	O
from	O
mice	B-OG
daily	O
with	O
callipers	O
.	O

Tumour	B-DS
volume	O
was	O
calculated	O
as	O
0	O
.	O
5	O
×	O
(	O
length	O
×	O
width2	O
).	O

Mice	B-OG
were	O
euthanized	O
when	O
primary	O
tumours	B-DS
reached	O
10	O
%	O
of	O
starting	O
body	O
weight	O
,	O
or	O
at	O
the	O
first	O
sign	O
of	O
discomfort	O
from	O
metastatic	O
burden	O
.	O

Tumours	B-DS
and	O
organ	O
sites	O
of	O
metastasis	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
and	O
frozen	O
.	O
14	O

Immunohistochemistry	O
(	O
IHC	O
)	O
and	O
immunocytochemistry	O
(	O
ICC	O
)	O

For	O
H	O
&	O
E	O
staining	O
,	O
sections	O
were	O
stained	O
with	O
Gill	O
'	O
s	O
hematoxylin	O
and	O
eosin	O
Y	O
and	O
then	O
scanned	O
at	O
20X	O
using	O
a	O
Zeiss	O
AxioScan	O
.	O
Z1	O
slide	O
scanner	O
.	O

The	O
following	O
primary	O
antibodies	O
were	O
used	O
for	O
IHC	O
/	O
ICC15	O
:	O
rabbit	B-OG
anti	O
-	O
Ki67	B-GP
(	O
1	O
:	O
5	O
,	O
000	O
;	O
Abcam	O
);	O
rabbit	B-OG
anti	O
-	O
activated	O
caspase	B-GP
-	I-GP
3	I-GP
(	O
1	O
:	O
200	O
;	O
R	O
&	O
D	O
Systems	O
);	O
rabbit	B-OG
anti	O
-	O
CD31	B-GP
(	O
Santa	O
Cruz	O
Biotechnology	O
);	O
mouse	B-OG
anti	O
-	O
skeletal	B-GP
myosin	I-GP
(	O
1	O
:	O
400	O
;	O
Sigma	O
);	O
rabbit	B-OG
anti	O
-	O
β1	O
(	O
1	O
:	O
200	O
;	O
Abgent	O
);	O
mouse	B-OG
anti	O
-	O
fyn	B-GP
(	O
1	O
:	O
100	O
;	O
BioLegend	O
);	O
mouse	B-OG
anti	O
-	O
CD44	B-GP
(	O
1	O
:	O
100	O
;	O
AbD	O
Serotec	O
);	O
rabbit	B-OG
anti	O
-	O
E	B-GP
-	I-GP
cadherin	I-GP
(	O
1	O
:	O
200	O
;	O
Cell	O
Signaling	O
Technology	O
);	O
mouse	B-OG
anti	O
-	O
human	B-OG
nuclear	O
antigen	O
(	O
HNA	O
;	O
1	O
:	O
100	O
;	O
Millipore	O
).	O

Secondary	O
antibodies	O
were	O
Alexa	O
-	O
568	O
-	O
conjugated	O
goat	B-OG
anti	O
mouse	B-OG
/	O
rabbit	B-OG
,	O
unless	O
stated	O
otherwise	O
(	O
1	O
:	O
500	O
;	O
Invitrogen	O
).	O

Samples	O
were	O
mounted	O
in	O
Prolong	O
Gold	O
with	O
DAPI	O
(	O
Invitrogen	O
).	O

Some	O
samples	O
were	O
stained	O
with	O
Alexa	O
-	O
633	O
-	O
phalloidin	O
(	O
1	O
:	O
25	O
;	O
Invitrogen	O
).	O
23	O
Samples	O
were	O
viewed	O
using	O
20	O
×	O
objectives	O
on	O
a	O
Nikon	O
Eclipse	O
TE200	O
fluorescent	O
microscope	O
,	O
or	O
Zeiss	O
Axio	O
Observer	O
.	O
Z1	O
microscope	O
with	O
LSM	O
710	O
confocal	O
laser	O
scanner	O
.	O

Image	O
analysis	O

Images	O
were	O
exported	O
into	O
ImageJ	O
for	O
processing	O
.	O

Confocal	O
Z	O
-	O
series	O
projections	O
were	O
flattened	O
using	O
the	O
maximum	O
signal	O
.	O

Brightness	O
/	O
contrast	O
was	O
adjusted	O
using	O
the	O
ImageJ	O
“	O
Auto	O
”	O
function	O
.	O

ICC	O
colocalization	O
was	O
evaluated	O
using	O
ImageJ	O
.	O

Intensity	O
correlation	O
analysis	O
(	O
ICA	O
)	O
was	O
performed	O
on	O
individual	O
cells	O
delineated	O
with	O
the	O
freehand	O
selection	O
tool	O
,	O
and	O
for	O
each	O
cell	O
,	O
the	O
intensity	O
correlation	O
quotient	O
(	O
ICQ	O
)	O
was	O
computed	O
.	O

For	O
signal	O
intensities	O
that	O
vary	O
together	O
,	O
indicating	O
colocalization	O
,	O
0	O
<	O
ICQ	O
≤	O
0	O
.	O
5	O
,	O
whereas	O
for	O
segregated	O
staining	O
,	O
−	O
0	O
.	O
5	O
≤	O
ICQ	O
<	O
0	O
.	O
30	O
Measurements	O
were	O
from	O
20	O
cells	O
per	O
line	O
.	O

The	O
following	O
measurements	O
were	O
made	O
on	O
IHC	O
sections	O
,	O
for	O
three	O
mice	B-OG
per	O
treatment	O
group	O
:	O

Density	O
of	O
Ki67	B-GP
+	O
or	O
activated	O
caspase	B-GP
-	I-GP
3	I-GP
+	O
cells17	O
:	O
the	O
number	O
of	O
Ki67	B-GP
+	O
nuclei	O
or	O
active	O
caspase	B-GP
-	I-GP
3	I-GP
+	O
cells	O
was	O
counted	O
per	O
20X	O
field	O
of	O
view	O
.	O

Tumour	B-DS
vascularity31	O
:	O
the	O
number	O
of	O
CD31	B-GP
+	O
vessels	O
was	O
counted	O
per	O
20X	O
field	O
of	O
view	O
.	O

Metastasis	O
to	O
liver	O
/	O
lungs	O
/	O
spleen32	O
:	O
the	O
number	O
of	O
GFP	B-GP
+	O
metastatic	O
foci	O
was	O
counted	O
per	O
20X	O
field	O
of	O
view	O
.	O

Length	O
of	O
tumour	B-DS
cell	O
processes	O
and	O
muscle	O
fibers	O
:	O
The	O
longest	O
visible	O
process	O
on	O
cancer	B-DS
cells	O
and	O
the	O
total	O
length	O
of	O
individual	O
muscle	O
fibers	O
within	O
20	O
×	O
fields	O
of	O
view	O
was	O
measured	O
using	O
the	O
freeform	O
line	O
function	O
in	O
ImageJ	O
.	O

VEGF	B-GP
ELISA	O

Cells	O
were	O
cultured	O
in	O
24	O
-	O
well	O
plates	O
(	O
5	O
×	O
104	O
/	O
well	O
).	O

After	O
1	O
,	O
2	O
,	O
and	O
3	O
days	O
,	O
culture	O
medium	O
was	O
removed	O
from	O
individual	O
wells	O
and	O
stored	O
at	O
−	O
20	O
°	O
C	O
until	O
analysis	O
.	O

VEGF	B-GP
secretion	O
was	O
determined	O
by	O
ELISA	O
(	O
Promega	O
).	O

Measurements	O
were	O
obtained	O
from	O
duplicate	O
wells	O
from	O
three	O
repeat	O
experiments	O
.	O

Process	O
outgrowth	O
assay	O

Process	O
outgrowth	O
assays	O
were	O
based	O
on	O
Ref	O
.	O
14	O
.	O

Parental	O
CHL	O
fibroblasts	O
or	O
CHL	O
fibroblasts	O
expressing	O
β1	O
were	O
grown	O
to	O
confluence	O
on	O
13mm	O
diameter	O
coverslips	O
.	O

Freshly	O
dissociated	O
BCa	B-DS
cells	O
were	O
plated	O
(	O
2	O
×	O
104	O
cells	O
/	O
well	O
)	O
on	O
top	O
of	O
the	O
monolayers	O
and	O
allowed	O
to	O
grow	O
for	O
24	O
–	O
48	O
h	O
.	O

Cultures	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
and	O
the	O
cancer	B-DS
cells	O
were	O
visualized	O
with	O
anti	O
-	O
GFP	B-GP
(	O
1	O
:	O
1	O
,	O
000	O
;	O
NeuroMab	O
),	O
or	O
anti	O
-	O
cytokeratin	B-GP
18	I-GP
(	O
1	O
:	O
500	O
;	O
BioLegend	O
)	O
followed	O
by	O
Alexa	O
-	O
568	O
-	O
conjugated	O
goat	B-OG
anti	O
-	O
mouse	B-OG
(	O
1	O
:	O
500	O
).	O

Images	O
were	O
acquired	O
using	O
a	O
Nikon	O
Eclipse	O
TE200	O
fluorescent	O
microscope	O
with	O
40	O
×	O
objective	O
.	O

The	O
longest	O
process	O
on	O
each	O
of	O
the	O
first	O
50	O
randomly	O
selected	O
,	O
isolated	O
cancer	B-DS
cells	O
was	O
measured	O
using	O
ImageJ	O
.	O

Measurements	O
were	O
obtained	O
from	O
three	O
independent	O
experiments	O
.	O

Deletion	O
of	O
β1	O
Ig	B-GP
domain	O

The	O
Ig	B-GP
domain	O
of	O
β1	O
(	O
amino	O
acids	O
40	O
–	O
124	O
)	O
in	O
pEGFPN124	O
was	O
deleted	O
using	O
the	O
Phusion	O
site	O
-	O
directed	O
mutagenesis	O
kit	O
(	O
Thermo	O
Scientific	O
).	O

The	O
β1Δ40	O
–	O
124	O
-	O
GFP	B-GP
construct	O
was	O
sequenced	O
,	O
and	O
then	O
transfected	O
into	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
using	O
Fugene	O
(	O
Roche	O
).	O
24	O

RNA	O
interference	O

SiGENOME	O
SMARTpool	O
siRNA	O
targeting	O
FYN	B-GP
and	O
siGENOME	O
Non	O
-	O
Targeting	O
siRNA	O
Pool	O
#	O
1	O
(	O
Dharmacon	O
)	O
were	O
used	O
at	O
50	O
nM	O
.	O

Transfection	O
was	O
performed	O
using	O
Dharmafect	O
1	O
reagent	O
.	O

Transfection	O
efficiency	O
was	O
confirmed	O
to	O
be	O
≥	O
90	O
%	O
using	O
siGENOME	O
positive	O
control	O
targeting	O
GAPDH	B-GP
(	O
Supporting	O
Information	O
Fig	O
.	O

S5c	O
).	O

RNA	O
extraction	O
and	O
process	O
outgrowth	O
assay	O
were	O
performed	O
96h	O
after	O
transfection	O
.	O

Data	O
analysis	O

Data	O
are	O
mean	O
and	O
SEM	O
unless	O
stated	O
otherwise	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
GraphPad	O
Prism	O
.	O

Matrix	O
data	O
were	O
plotted	O
using	O
Matrix2png	O
software	O
.	O
33	O
Statistical	O
significance	O
was	O
determined	O
with	O
t	O
tests	O
or	O
Mann	O
–	O
Whitney	O
tests	O
,	O
and	O
multiple	O
comparisons	O
were	O
made	O
using	O
ANOVA	O
and	O
Tukey	O
post	O
hoc	O
tests	O
,	O
unless	O
stated	O
otherwise	O
.	O
p	O
values	O
computed	O
by	O
Oncomine	O
were	O
corrected	O
for	O
multiple	O
comparisons	O
by	O
Bonferroni	O
method	O
.	O

Correlation	O
between	O
ESR1	B-GP
and	O
SCN1B	B-GP
expression	O
was	O
determined	O
using	O
Pearson	O
'	O
s	O
r	O
test	O
.	O

Association	O
between	O
categorical	O
classification	O
criteria	O
was	O
determined	O
with	O
Fisher	O
'	O
s	O
exact	O
test	O
,	O
or	O
χ2	O
test	O
.	O

For	O
meta	O
-	O
analysis	O
of	O
association	O
between	O
SCN1B	B-GP
expression	O
and	O
histoclinical	O
characteristics	O
across	O
multiple	O
datasets	O
,	O
the	O
binomial	O
test	O
was	O
used	O
.	O
26	O
The	O
binomial	O
test	O
p	O
value	O
indicates	O
whether	O
or	O
not	O
one	O
criterion	O
was	O
associated	O
with	O
another	O
in	O
the	O
observed	O
number	O
of	O
datasets	O
by	O
chance	O
,	O
given	O
the	O
number	O
of	O
datasets	O
studied	O
.	O

Kaplan	O
–	O
Meier	O
curves	O
for	O
survival	O
were	O
compared	O
by	O
log	O
-	O
rank	O
tests	O
.	O

Percent	O
survival	O
and	O
hazard	O
ratios	O
are	O
presented	O
with	O
95	O
%	O
confidence	O
intervals	O
.	O

Results	O
were	O
considered	O
significant	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

Results	O

β1	O
mRNA	O
and	O
protein	O
are	O
present	O
in	O
breast	B-DS
tumours	I-DS

We	O
have	O
previously	O
shown	O
that	O
β1	O
mRNA	O
/	O
protein	O
are	O
expressed	O
in	O
BCa	B-DS
cell	O
lines	O
.	O
24	O
Here	O
,	O
we	O
used	O
Oncomine	O
to	O
study	O
the	O
expression	O
of	O
SCN1B	B-GP
mRNA	O
in	O
normal	O
breast	O
and	O
BCa	B-DS
specimens	O
across	O
multiple	O
microarrays	O
.	O
SCN1B	B-GP
was	O
expressed	O
at	O
a	O
significantly	O
higher	O
level	O
in	O
BCa	B-DS
compared	O
with	O
normal	O
breast	O
in	O
two	O
out	O
of	O
eight	O
datasets	O
in	O
which	O
differential	O
data	O
were	O
available	O
(	O
1	O
.	O
7	O
-	O
fold	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
and	O
>	O
2	O
.	O
2	O
-	O
fold	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
Figs	O
.	O

1a	O
and	O
1b	O
).	O

We	O
next	O
performed	O
a	O
meta	O
-	O
analysis	O
to	O
investigate	O
whether	O
SCN1B	B-GP
expression	O
correlates	O
with	O
histoclinical	O
characteristics	O
across	O
multiple	O
datasets	O
.	O

High	O
SCN1B	B-GP
expression	O
associated	O
with	O
ER	O
status	O
in	O
8	O
/	O
21	O
(	O
38	O
.	O
1	O
%)	O
of	O
datasets	O
(	O
p	O
<	O
0	O
.	O
0001	O
;	O
Supporting	O
Information	O
Table	O
S2	O
;	O
Figs	O
.	O

S1a	O
and	O
S1b	O
).	O

There	O
was	O
no	O
significant	O
association	O
between	O
SCN1B	B-GP
and	O
age	O
,	O
pathological	O
tumour	B-DS
size	O
,	O
grade	O
,	O
recurrence	O
,	O
progesterone	B-GP
receptor	I-GP
,	O
or	O
HER2	B-GP
status	O
across	O
the	O
same	O
datasets	O
.	O

Up	O
-	O
regulation	O
of	O
SCN1B	B-GP
expression	O
in	O
ER	O
+	O
tumours	B-DS
correlated	O
with	O
several	O
genomic	O
neighbours	O
on	O
chromosome	O
19q	O
(	O
Supporting	O
Information	O
Fig	O
.	O

S1c	O
).	O
26	O
However	O
,	O
mRNA	O
levels	O
of	O
the	O
two	O
SCN1B	B-GP
splice	O
variants	O
,	O
β1	O
and	O
β1B	O
,	O
34	O
which	O
are	O
both	O
expressed	O
across	O
a	O
panel	O
of	O
BCa	B-DS
cell	O
lines	O
(	O
Supporting	O
Information	O
Figs	O
.	O

S1d	O
and	O
S1e	O
),	O
were	O
unchanged	O
in	O
MCF	O
-	O
7	O
cells	O
following	O
treatment	O
with	O
estrogen	O
or	O
fulvestrant	O
(	O
Supporting	O
Information	O
Fig	O
.	O

S1f	O
),	O
suggesting	O
that	O
SCN1B	B-GP
is	O
not	O
estrogen	O
-	O
regulated	O
.	O

β1	O
mRNA	O
and	O
protein	O
expression	O
in	O
breast	B-DS
cancer	I-DS
.	O

(	O
a	O
)	O
Expression	O
of	O
SCN1B	B-GP
mRNA	O
in	O
invasive	B-DS
lobular	I-DS
breast	I-DS
carcinoma	I-DS
(	O
ILBCa	B-DS
)	O
vs	O
.	O
normal	O
in	O
the	O
Radvanyi	O
Breast	O
dataset	O
(	O
n	O
=	O
15	O
).	O

(	O
b	O
)	O
Expression	O
of	O
SCN1B	B-GP
in	O
invasive	B-DS
ductal	I-DS
breast	I-DS
cancer	I-DS
(	O
IDBCa	B-DS
)	O
and	O
ILBCa	B-DS
in	O
the	O
Turashvili	O
Breast	O
dataset	O
(	O
n	O
=	O
30	O
).	O

Box	O
plot	O
dots	O
,	O
maximum	O
and	O
minimum	O
values	O
;	O
whiskers	O
,	O
90th	O
and	O
10th	O
percentile	O
values	O
;	O
and	O
horizontal	O
lines	O
,	O
75th	O
,	O
50th	O
,	O
and	O
25th	O
percentile	O
values	O
.	O

(	O
c	O
)	O
Representative	O
images	O
of	O
non	O
-	O
cancer	B-DS
breast	O
tissue	O
and	O
(	O
d	O
)	O
breast	B-DS
tumour	I-DS
tissue	O
in	O
which	O
β1	O
was	O
(	O
i	O
)	O
absent	O
,	O
(	O
ii	O
)	O
weakly	O
positive	O
,	O
and	O
(	O
iii	O
)	O
strongly	O
positive	O
.	O

Scale	O
bar	O
,	O
100	O
µm	O
.	O

Insets	O
,	O
higher	O
magnification	O
images	O
of	O
tumour	B-DS
cells	O
,	O
scale	O
bar	O
,	O
50µm	O
.	O

(	O
e	O
)	O
Mean	O
Allred	O
score	O
for	O
normal	O
breast	O
and	O
tumour	B-DS
samples	O
.	O

Data	O
are	O
mean	O
±	O
SEM	O
(	O
n	O
=	O
66	O
).	O

(	O
f	O
)	O
Kaplan	O
–	O
Meier	O
analysis	O
comparing	O
BCa	B-DS
-	O
specific	O
survival	O
of	O
those	O
with	O
“	O
low	O
”	O
(	O
score	O
<	O
5	O
)	O
vs	O
.	O
“	O
high	O
”	O
(	O
score	O
≥	O
5	O
)	O
β1	O
expression	O
(	O
n	O
=	O
62	O
).	O

(	O
g	O
)	O
Western	O
blot	O
of	O
β1	O
and	O
fyn	B-GP
in	O
the	O
MCF	O
-	O
10A	O
non	O
-	O
cancer	B-DS
mammary	O
epithelial	O
cell	O
line	O
.	O

(	O
h	O
)	O
Western	O
blot	O
of	O
β1	O
and	O
fyn	B-GP
across	O
a	O
panel	O
of	O
BCa	B-DS
cell	O
lines	O
.	O

Positive	O
control	O
=	O
rat	B-OG
brain	O
lysate	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

We	O
next	O
studied	O
the	O
expression	O
of	O
β1	O
at	O
protein	O
level	O
in	O
human	B-OG
tissue	O
samples	O
by	O
IHC	O
.	O
β1	O
immunoreactivity	O
was	O
mainly	O
in	O
the	O
cytoplasm	O
of	O
epithelial	O
and	O
carcinoma	B-DS
cells	O
,	O
with	O
variable	O
expression	O
at	O
the	O
plasma	O
membrane	O
(	O
Figs	O
.	O

1c	O
and	O
1d	O
).	O

This	O
pattern	O
of	O
expression	O
is	O
consistent	O
with	O
previous	O
observations	O
in	O
neurons	O
and	O
cancer	B-DS
cell	O
lines	O
.	O
14	O
,	O
16	O
,	O
23	O
β1	O
expression	O
was	O
significantly	O
higher	O
in	O
tumour	B-DS
than	O
normal	O
,	O
non	O
-	O
cancer	B-DS
breast	O
tissue	O
samples	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Fig	O
.	O
1e	O
).	O

Of	O
the	O
cases	O
where	O
tumour	B-DS
had	O
matched	O
surrounding	O
non	O
-	O
cancer	B-DS
tissue	O
,	O
27	O
(	O
68	O
%)	O
had	O
higher	O
β1	O
in	O
tumour	B-DS
than	O
non	O
-	O
cancer	B-DS
tissue	O
,	O
7	O
(	O
17	O
%)	O
had	O
the	O
same	O
level	O
of	O
β1	O
in	O
tumour	B-DS
and	O
non	O
-	O
cancer	B-DS
tissue	O
,	O
and	O
6	O
(	O
15	O
%)	O
had	O
lower	O
expression	O
in	O
tumour	B-DS
than	O
non	O
-	O
cancer	B-DS
tissue	O
.	O
β1	O
expression	O
in	O
the	O
tumour	B-DS
did	O
not	O
correlate	O
with	O
age	O
,	O
ER	O
status	O
,	O
grade	O
,	O
menopausal	O
status	O
,	O
or	O
node	O
status	O
(	O
Supporting	O
Information	O
Table	O
S3	O
).	O

Similarly	O
,	O
there	O
was	O
no	O
relationship	O
with	O
BCa	B-DS
-	O
specific	O
survival	O
(	O
Fig	O
.	O
1f	O
,	O
Supporting	O
Information	O
Table	O
S3	O
).	O

In	O
agreement	O
with	O
the	O
IHC	O
data	O
,	O
β1	O
was	O
also	O
expressed	O
at	O
protein	O
level	O
in	O
the	O
non	O
-	O
cancer	B-DS
mammary	O
epithelial	O
MCF	O
-	O
10A	O
cell	O
line	O
and	O
across	O
a	O
panel	O
of	O
BCa	B-DS
cell	O
lines	O
(	O
Figs	O
.	O

1g	O
and	O
1h	O
).	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
β1	O
may	O
be	O
up	O
-	O
regulated	O
in	O
a	O
unique	O
subset	O
of	O
breast	B-DS
cancers	I-DS
at	O
mRNA	O
and	O
protein	O
level	O
.	O

β1	O
promotes	O
tumour	B-DS
growth	O
and	O
vascularization	O

We	O
next	O
investigated	O
the	O
role	O
of	O
β1	O
in	O
tumour	B-DS
growth	O
and	O
metastasis	O
.	O

We	O
orthotopically	O
implanted	O
luciferase	B-GP
-	O
expressing	O
MDA	O
-	O
MB	O
-	O
231	O
or	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
into	O
the	O
mammary	O
fat	O
pads	O
of	O
female	O
Rag2	B-GP
−/−	O
Il2rg	B-GP
−/−	O
mice	B-OG
and	O
monitored	O
tumour	B-DS
growth	O
by	O
bioluminescent	O
imaging	O
.	O

We	O
chose	O
this	O
model	O
because	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
rapidly	O
form	O
palpable	O
tumours	B-DS
following	O
orthotopic	O
implantation	O
,	O
and	O
the	O
cells	O
readily	O
metastasise	O
.	O

MDA	O
-	O
MB	O
-	O
231	O
cells	O
express	O
very	O
low	O
endogenous	O
β1	O
(	O
Supporting	O
Information	O
Fig	O
.	O

S2a	O
).	O

By	O
contrast	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
over	O
-	O
express	O
β1	O
-	O
GFP	B-GP
by	O
>	O
40	O
-	O
fold	O
relative	O
to	O
endogenous	O
β1	O
(	O
Supporting	O
Information	O
Figs	O
.	O

S2a	O
and	O
S2b	O
).	O
24	O
Over	O
-	O
expression	O
of	O
β1	O
had	O
no	O
effect	O
on	O
expression	O
of	O
CD44	B-GP
or	O
E	B-GP
-	I-GP
cadherin	I-GP
(	O
Supporting	O
Information	O
Figs	O
.	O

S2c	O
–	O
S2e	O
).	O

Importantly	O
,	O
luciferase	B-GP
activity	O
and	O
GFP	B-GP
expression	O
were	O
very	O
similar	O
in	O
both	O
cell	O
lines	O
(	O
Supporting	O
Information	O
Figs	O
.	O

S3a	O
–	O
S3d	O
).	O

Photon	O
flux	O
from	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
tumours	B-DS
increased	O
faster	O
than	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
tumours	B-DS
,	O
becoming	O
statistically	O
significant	O
after	O
4	O
weeks	O
(	O
Figs	O
.	O

2a	O
and	O
2b	O
).	O

To	O
confirm	O
the	O
bioluminescent	O
imaging	O
data	O
,	O
we	O
also	O
analyzed	O
tumour	B-DS
growth	O
by	O
daily	O
calliper	O
measurement	O
.	O

The	O
volume	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
tumours	B-DS
increased	O
more	O
rapidly	O
than	O
MDA	O
-	O
MB	O
-	O
231	O
tumours	B-DS
,	O
closely	O
agreeing	O
with	O
the	O
bioluminescent	O
data	O
(	O
Fig	O
.	O
2c	O
).	O

During	O
the	O
5	O
-	O
week	O
study	O
period	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
primary	O
tumour	B-DS
burden	O
reached	O
10	O
%	O
of	O
starting	O
body	O
weight	O
in	O
71	O
%	O
of	O
mice	B-OG
,	O
compared	O
with	O
only	O
17	O
%	O
for	O
control	O
tumours	B-DS
(	O
Fig	O
.	O
2d	O
).	O

The	O
survival	O
of	O
mice	B-OG
bearing	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
tumours	B-DS
was	O
significantly	O
reduced	O
compared	O
to	O
those	O
bearing	O
control	O
tumours	B-DS
(	O
p	O
<	O
0	O
.	O
05	O
;	O
hazard	O
ratio	O
=	O
6	O
.	O
3	O
[	O
1	O
.	O
4	O
–	O
27	O
.	O
8	O
];	O
Fig	O
.	O
2e	O
).	O

These	O
data	O
demonstrate	O
that	O
over	O
-	O
expression	O
of	O
β1	O
enhanced	O
the	O
growth	O
of	O
breast	B-DS
tumours	I-DS
,	O
thus	O
reducing	O
survival	O
.	O

Effect	O
of	O
β1	O
over	O
-	O
expression	O
on	O
breast	B-DS
tumour	I-DS
growth	O
in	O
vivo	O
.	O

MDA	O
-	O
MB	O
-	O
231	O
(“	O
Control	O
”)	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
(“	O
β1	O
”)	O
cells	O
were	O
implanted	O
into	O
the	O
inguinal	O
mammary	O
fat	O
pads	O
of	O
female	O
Rag2	B-GP
−/−	O
Il2rg	B-GP
−/−	O
mice	B-OG
.	O

(	O
a	O
)	O
Representative	O
bioluminescent	O
images	O
of	O
mice	B-OG
bearing	O
control	O
and	O
β1	O
tumours	B-DS
,	O
4	O
weeks	O
after	O
implantation	O
.	O

(	O
b	O
)	O
Bioluminescence	O
measured	O
from	O
primary	O
tumours	B-DS
on	O
the	O
indicated	O
days	O
post	O
-	O
implantation	O
(	O
n	O
≥	O
12	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
.	O

(	O
c	O
)	O
Calculated	O
volume	O
derived	O
from	O
calliper	O
measurement	O
of	O
primary	O
tumours	B-DS
over	O
the	O
same	O
period	O
(	O
n	O
≥	O
12	O
).	O

(	O
d	O
)	O
Percentage	O
of	O
mice	B-OG
whose	O
primary	O
tumour	B-DS
burden	O
reached	O
10	O
%	O
of	O
starting	O
body	O
weight	O
within	O
the	O
5	O
-	O
week	O
tumour	B-DS
growth	O
period	O
is	O
shown	O
for	O
control	O
and	O
β1	O
tumours	B-DS
.	O

(	O
e	O
)	O
Kaplan	O
–	O
Meier	O
analysis	O
comparing	O
overall	O
survival	O
of	O
mice	B-OG
bearing	O
control	O
and	O
β1	O
tumours	B-DS
(	O
n	O
=	O
13	O
).	O

(	O
f	O
)	O
Images	O
of	O
control	O
and	O
β1	O
tumour	B-DS
tissue	O
sections	O
stained	O
with	O
H	O
&	O
E	O
showing	O
(	O
i	O
)	O
mammary	O
fat	O
pad	O
and	O
(	O
ii	O
)	O
skeletal	O
muscle	O
invasion	O
.	O

Arrows	O
,	O
infiltration	O
of	O
tumour	B-DS
cells	O
(	O
T	O
)	O
into	O
fibroadipose	O
tissue	O
(	O
F	O
)	O
or	O
skeletal	O
muscle	O
fibers	O
(	O
M	O
).	O

Scale	O
bar	O
,	O
100	O
µm	O
.	O

Insets	O
,	O
higher	O
magnification	O
images	O
of	O
invading	O
tumour	B-DS
cells	O
,	O
scale	O
bar	O
,	O
50	O
µm	O
.	O

(	O
G	O
)	O
Invasion	O
of	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
±	O
TTX	O
(	O
30	O
µM	O
)	O
for	O
48	O
hr	O
(	O
n	O
=	O
12	O
;	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
Neuman	O
–	O
Keuls	O
test	O
).	O

We	O
next	O
studied	O
the	O
structure	O
and	O
composition	O
of	O
the	O
primary	O
tumours	B-DS
.	O

Both	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
tumours	B-DS
were	O
broadly	O
similar	O
,	O
containing	O
some	O
invasion	O
into	O
surrounding	O
fibroadipose	O
tissue	O
and	O
skeletal	O
muscle	O
(	O
Fig	O
.	O
2f	O
).	O

Although	O
the	O
in	O
vitro	O
invasiveness	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
was	O
moderately	O
higher	O
than	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
,	O
blockade	O
of	O
α	O
subunits	O
with	O
TTX	O
inhibited	O
invasion	O
of	O
both	O
cell	O
lines	O
to	O
a	O
similar	O
extent	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Fig	O
.	O
2g	O
).	O

Thus	O
,	O
α	O
-	O
subunit	O
-	O
dependent	O
invasion	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
cells20	O
,	O
21	O
appears	O
to	O
be	O
unaffected	O
by	O
β1	O
over	O
-	O
expression	O
.	O

The	O
density	O
of	O
Ki67	B-GP
+	O
cycling	O
cells	O
was	O
unchanged	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
tumours	B-DS
,	O
compared	O
to	O
control	O
tumours	B-DS
(	O
Figs	O
.	O

3a	O
and	O
3b	O
).	O

However	O
,	O
the	O
density	O
of	O
apoptotic	O
cells	O
expressing	O
activated	O
caspase	B-GP
-	I-GP
3	I-GP
was	O
significantly	O
reduced	O
by	O
84	O
%	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
tumours	B-DS
,	O
compared	O
to	O
control	O
tumours	B-DS
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Figs	O
.	O

3c	O
and	O
3d	O
).	O
In	O
vitro	O
,	O
staurosporine	O
-	O
induced	O
apoptosis	O
was	O
significantly	O
reduced	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
,	O
compared	O
to	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
(	O
Figs	O
.	O

3e	O
and	O
3f	O
),	O
suggesting	O
,	O
together	O
with	O
the	O
tumour	B-DS
data	O
,	O
that	O
β1	O
over	O
-	O
expression	O
enhances	O
resistance	O
to	O
apoptosis	O
.	O

Finally	O
,	O
the	O
density	O
of	O
vascular	O
structures	O
,	O
revealed	O
by	O
labelling	O
blood	O
vessels	O
with	O
an	O
antibody	O
to	O
the	O
endothelial	O
marker	O
CD31	B-GP
,	O
significantly	O
increased	O
by	O
1	O
.	O
5	O
-	O
fold	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
tumours	B-DS
,	O
compared	O
to	O
control	O
tumours	B-DS
,	O
and	O
VEGF	B-GP
secretion	O
in	O
vitro	O
was	O
significantly	O
higher	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
than	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
(	O
p	O
<	O
0	O
.	O
01	O
;	O
Figs	O
.	O

3g	O
−	O
3i	O
).	O

In	O
summary	O
,	O
these	O
data	O
suggest	O
that	O
β1	O
over	O
-	O
expression	O
increased	O
the	O
growth	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
tumours	B-DS
,	O
not	O
by	O
altering	O
the	O
density	O
of	O
cycling	O
cells	O
in	O
the	O
population	O
,	O
but	O
,	O
instead	O
by	O
reducing	O
apoptosis	O
and	O
enhancing	O
angiogenesis	O
.	O

Effect	O
of	O
β1	O
upregulation	O
on	O
proliferation	O
,	O
apoptosis	O
and	O
angiogenesis	O
.	O

(	O
a	O
)	O
Control	O
and	O
β1	O
tumour	B-DS
sections	O
stained	O
with	O
anti	O
-	O
Ki67	B-GP
(	O
red	O
)	O
and	O
DAPI	O
(	O
blue	O
).	O

Scale	O
bar	O
,	O
20	O
µm	O
.	O

(	O
b	O
)	O
Ki67	B-GP
-	O
positive	O
nuclei	O
per	O
field	O
of	O
view	O
for	O
control	O
and	O
β1	O
tumours	B-DS
(	O
n	O
=	O
30	O
).	O

(	O
c	O
)	O
Control	O
and	O
β1	O
tumour	B-DS
sections	O
stained	O
with	O
anti	O
-	O
activated	O
caspase	B-GP
-	I-GP
3	I-GP
(	O
red	O
)	O
and	O
DAPI	O
(	O
blue	O
).	O

Scale	O
bar	O
,	O
20	O
µm	O
.	O

(	O
d	O
)	O
Activated	O
caspase	B-GP
-	I-GP
3	I-GP
-	O
positive	O
cells	O
per	O
field	O
of	O
view	O
for	O
control	O
and	O
β1	O
tumours	B-DS
(	O
n	O
=	O
30	O
).	O

(	O
e	O
)	O
Images	O
of	O
control	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
treated	O
for	O
24	O
hr	O
with	O
/	O
without	O
0	O
.	O
5	O
µM	O
staurosporine	O
,	O
analyzed	O
by	O
TUNEL	O
assay	O
(	O
red	O
),	O
counterstained	O
with	O
DAPI	O
(	O
blue	O
).	O

Scale	O
bar	O
,	O
100	O
µm	O
.	O

(	O
f	O
)	O
Proportion	O
(%)	O
of	O
TUNEL	O
-	O
positive	O
nuclei	O
per	O
field	O
of	O
view	O
(	O
n	O
=	O
60	O
).	O

(	O
g	O
)	O
Blood	O
vessels	O
stained	O
with	O
endothelial	O
marker	O
CD31	B-GP
(	O
red	O
)	O
and	O
DAPI	O
(	O
blue	O
)	O
in	O
control	O
and	O
β1	O
tumour	B-DS
sections	O
.	O

Scale	O
bar	O
,	O
20	O
µm	O
.	O

(	O
h	O
)	O
CD31	B-GP
-	O
positive	O
blood	O
vessels	O
per	O
field	O
of	O
view	O
for	O
control	O
and	O
β1	O
tumours	B-DS
(	O
n	O
=	O
30	O
).	O

(	O
i	O
)	O
VEGF	B-GP
content	O
of	O
culture	O
medium	O
of	O
control	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
1	O
–	O
3	O
days	O
after	O
plating	O
(	O
n	O
=	O
6	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
;	O
**	O
p	O
<	O
0	O
.	O
01	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

β1	O
potentiates	O
metastasis	O
to	O
liver	O
and	O
lungs	O

We	O
monitored	O
metastasis	O
after	O
5	O
weeks	O
by	O
bioluminescent	O
imaging	O
following	O
post	O
mortem	O
resection	O
of	O
primary	O
tumours	B-DS
(	O
Fig	O
.	O
4a	O
).	O

Although	O
photon	O
flux	O
was	O
slightly	O
increased	O
in	O
mice	B-OG
bearing	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
tumours	B-DS
compared	O
those	O
bearing	O
MDA	O
-	O
MB	O
-	O
231	O
tumours	B-DS
,	O
and	O
in	O
the	O
liver	O
and	O
lungs	O
ex	O
vivo	O
,	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
Figs	O
.	O

4b	O
and	O
4c	O
).	O

To	O
study	O
metastasis	O
to	O
these	O
organs	O
in	O
more	O
detail	O
at	O
the	O
cellular	O
level	O
,	O
using	O
a	O
more	O
sensitive	O
method	O
,	O
we	O
measured	O
the	O
density	O
of	O
GFP	B-GP
-	O
expressing	O
tumour	B-DS
cells	O
within	O
tissue	O
sections	O
.	O

We	O
detected	O
GFP	B-GP
+	O
cells	O
in	O
sections	O
both	O
in	O
isolation	O
,	O
and	O
in	O
multicellular	O
foci	O
(	O
Figs	O
.	O

4d	O
,	O
4f	O
,	O
and	O
4h	O
).	O

GFP	B-GP
was	O
co	O
-	O
expressed	O
in	O
cells	O
with	O
HNA	O
(	O
Fig	O
.	O

S3e	O
).	O

HNA	O
is	O
present	O
in	O
human	B-OG
MDA	O
-	O
MB	O
-	O
231	O
cells	O
,	O
but	O
absent	O
in	O
mouse	B-OG
cells	O
,	O
thus	O
confirming	O
that	O
GFP	B-GP
expression	O
was	O
retained	O
in	O
the	O
tumour	B-DS
cells	O
once	O
they	O
had	O
metastasized	O
.	O

In	O
the	O
spleen	O
,	O
the	O
number	O
of	O
GFP	B-GP
+	O
cells	O
per	O
field	O
of	O
view	O
was	O
unchanged	O
between	O
groups	O
(	O
Fig	O
.	O
4e	O
).	O

However	O
,	O
the	O
number	O
of	O
GFP	B-GP
+	O
cells	O
per	O
field	O
of	O
view	O
was	O
significantly	O
increased	O
,	O
by	O
5	O
.	O
9	O
-	O
and	O
3	O
.	O
0	O
-	O
fold	O
,	O
respectively	O
,	O
in	O
the	O
liver	O
and	O
lungs	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
tumour	B-DS
-	O
bearing	O
mice	B-OG
,	O
compared	O
to	O
control	O
(	O
p	O
<	O
0	O
.	O
05	O
and	O
0	O
.	O
001	O
,	O
respectively	O
;	O
Figs	O
.	O

4g	O
and	O
4i	O
).	O

Thus	O
,	O
β1	O
over	O
-	O
expression	O
promoted	O
metastasis	O
to	O
the	O
liver	O
and	O
lungs	O
,	O
but	O
not	O
the	O
spleen	O
.	O

Effect	O
of	O
β1	O
over	O
-	O
expression	O
on	O
breast	B-DS
cancer	I-DS
metastasis	O
in	O
vivo	O
.	O

At	O
5	O
weeks	O
following	O
implantation	O
,	O
control	O
and	O
β1	O
tumours	B-DS
were	O
removed	O
post	O
mortem	O
prior	O
to	O
bioluminescent	O
imaging	O
.	O

(	O
a	O
)	O
Representative	O
bioluminescent	O
images	O
of	O
metastases	O
from	O
control	O
and	O
β1	O
tumours	B-DS
.	O

(	O
b	O
)	O
Bioluminescence	O
measured	O
from	O
the	O
indicated	O
anatomical	O
sites	O
from	O
control	O
and	O
β1	O
tumour	B-DS
-	O
bearing	O
mice	B-OG
(	O
n	O
≥	O
5	O
).	O

(	O
c	O
)	O
Bioluminescence	O
measured	O
ex	O
vivo	O
from	O
the	O
spleen	O
,	O
liver	O
,	O
and	O
lungs	O
of	O
control	O
and	O
β1	O
tumour	B-DS
-	O
bearing	O
mice	B-OG
(	O
n	O
≥	O
5	O
).	O

(	O
d	O
)	O
Spleen	O
sections	O
from	O
control	O
and	O
β1	O
tumour	B-DS
-	O
bearing	O
mice	B-OG
showing	O
GFP	B-GP
signal	O
(	O
green	O
)	O
and	O
DAPI	O
(	O
blue	O
).	O

(	O
e	O
)	O
GFP	B-GP
-	O
positive	O
cells	O
per	O
field	O
of	O
view	O
of	O
spleen	O
(	O
n	O
=	O
30	O
).	O

(	O
f	O
)	O
Liver	O
sections	O
from	O
control	O
and	O
β1	O
tumour	B-DS
-	O
bearing	O
mice	B-OG
showing	O
GFP	B-GP
signal	O
(	O
green	O
)	O
and	O
DAPI	O
(	O
blue	O
).	O

(	O
g	O
)	O
GFP	B-GP
-	O
positive	O
cells	O
per	O
field	O
of	O
view	O
of	O
liver	O
(	O
n	O
=	O
30	O
).	O

(	O
h	O
)	O
Lung	O
sections	O
from	O
control	O
and	O
β1	O
tumour	B-DS
-	O
bearing	O
mice	B-OG
showing	O
GFP	B-GP
signal	O
and	O
DAPI	O
(	O
blue	O
).	O

(	O
i	O
)	O
GFP	B-GP
-	O
positive	O
cells	O
per	O
field	O
of	O
view	O
of	O
lung	O
(	O
n	O
=	O
30	O
).	O

Bars	O
are	O
mean	O
+	O
SEM	O
;	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

Scale	O
bar	O
,	O
100	O
µm	O
.	O

β1	O
promotes	O
process	O
outgrowth	O

Enhancement	O
of	O
protrusions	O
,	O
e	O
.	O
g	O
.,	O
pseudopodia	O
,	O
from	O
cells	O
is	O
associated	O
with	O
increased	O
motility	O
in	O
3D	O
cultures	O
,	O
invasion	O
,	O
and	O
metastasis	O
.	O
35	O
–	O
37	O
Over	O
-	O
expression	O
of	O
β1	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
increases	O
the	O
length	O
of	O
processes	O
protruding	O
from	O
the	O
cell	O
body	O
in	O
vitro	O
.	O
24	O
We	O
therefore	O
postulated	O
that	O
β1	O
might	O
regulate	O
cellular	O
morphology	O
in	O
our	O
tumour	B-DS
model	O
.	O

In	O
the	O
periphery	O
of	O
tumour	B-DS
sections	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
infiltrating	O
surrounding	O
skeletal	O
muscle	O
appeared	O
more	O
densely	O
packed	O
,	O
and	O
had	O
a	O
more	O
elongate	O
morphology	O
than	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
(	O
Fig	O
.	O
5a	O
).	O

In	O
these	O
sections	O
,	O
processes	O
extending	O
from	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
were	O
significantly	O
longer	O
than	O
processes	O
on	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
(	O
Fig	O
.	O
5b	O
).	O

The	O
length	O
of	O
muscle	O
fibers	O
was	O
unchanged	O
between	O
tumour	B-DS
types	O
(	O
Fig	O
.	O
5c	O
).	O

Effect	O
of	O
β1	O
on	O
process	O
outgrowth	O
in	O
breast	B-DS
cancer	I-DS
cells	O
.	O

(	O
a	O
)	O
Regions	O
of	O
skeletal	O
muscle	O
infiltration	O
in	O
control	O
(	O
i	O
,	O
iii	O
,	O
v	O
)	O
and	O
β1	O
(	O
ii	O
,	O
iv	O
,	O
vi	O
)	O
tumour	B-DS
sections	O
showing	O
GFP	B-GP
signal	O
(	O
green	O
)	O
and	O
skeletal	B-GP
fast	I-GP
myosin	I-GP
(	O
red	O
).	O

Arrows	O
indicate	O
cells	O
in	O
β1	O
tumours	B-DS
that	O
have	O
more	O
elongate	O
processes	O
.	O

Scale	O
bar	O
,	O
50	O
µm	O
.	O

Insets	O
,	O
higher	O
magnification	O
images	O
of	O
tumour	B-DS
cells	O
showing	O
processes	O
.	O

Inset	O
scale	O
bar	O
,	O
10	O
µm	O
.	O

(	O
b	O
)	O
Process	O
length	O
(	O
µm	O
)	O
of	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
in	O
tumours	B-DS
(	O
n	O
≥	O
134	O
cells	O
/	O
each	O
).	O

(	O
c	O
)	O
Length	O
(	O
µm	O
)	O
of	O
muscle	O
fibers	O
in	O
control	O
and	O
β1	O
tumours	B-DS
(	O
n	O
≥	O
79	O
).	O

(	O
d	O
)	O
Images	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
grown	O
on	O
control	O
or	O
β1	O
-	O
expressing	O
CHL	O
fibroblast	O
monolayers	O
,	O
and	O
stained	O
with	O
anti	O
-	O
GFP	B-GP
antibody	O
.	O

Scale	O
bar	O
,	O
20	O
µm	O
.	O

(	O
e	O
)	O
Process	O
length	O
(	O
µm	O
)	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
grown	O
on	O
control	O
or	O
β1	O
-	O
expressing	O
CHL	O
monolayers	O
(	O
n	O
=	O
300	O
).	O

(	O
f	O
)	O
Process	O
length	O
(	O
µm	O
)	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1Δ40	O
–	O
124	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
grown	O
on	O
control	O
or	O
β1	O
-	O
expressing	O
CHL	O
monolayers	O
(	O
n	O
=	O
300	O
).	O

(	O
g	O
)	O
Process	O
length	O
(	O
µm	O
)	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
grown	O
on	O
control	O
or	O
β1	O
-	O
expressing	O
CHL	O
monolayers	O
±	O
30	O
µM	O
TTX	O
(	O
n	O
≥	O
144	O
).	O

(	O
h	O
)	O
Process	O
length	O
(	O
µm	O
)	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
grown	O
on	O
control	O
or	O
β1	O
-	O
expressing	O
CHL	O
monolayers	O
±	O
30	O
µM	O
TTX	O
(	O
n	O
=	O
150	O
).	O

Bars	O
are	O
mean	O
+	O
SEM	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

In	O
the	O
nervous	O
system	O
,	O
β1	O
regulates	O
neuronal	O
morphology	O
and	O
neurite	O
outgrowth	O
via	O
trans	O
-	O
homophilic	O
adhesion	O
.	O
15	O
We	O
therefore	O
set	O
out	O
to	O
test	O
the	O
hypothesis	O
that	O
this	O
neuronal	O
function	O
of	O
β1	O
is	O
recapitulated	O
when	O
it	O
is	O
expressed	O
in	O
BCa	B-DS
cells	O
,	O
enhancing	O
process	O
outgrowth	O
.	O

We	O
examined	O
the	O
morphology	O
of	O
BCa	B-DS
cells	O
plated	O
on	O
monolayers	O
of	O
control	O
and	O
β1	O
-	O
expressing	O
CHL	O
fibroblasts	O
.	O

CHL	O
cells	O
were	O
chosen	O
because	O
they	O
do	O
not	O
express	O
endogenous	O
β	O
subunits	O
.	O
14	O
When	O
plated	O
on	O
CHL	O
cells	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
produced	O
thin	O
processes	O
with	O
foci	O
at	O
the	O
tips	O
,	O
morphologically	O
similar	O
to	O
neurites	O
with	O
growth	O
cones	O
(	O
Fig	O
.	O
5d	O
).	O
15	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
did	O
not	O
show	O
any	O
increase	O
in	O
process	O
length	O
when	O
grown	O
on	O
β1	O
-	O
expressing	O
monolayers	O
(	O
Fig	O
.	O
5e	O
).	O

However	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
did	O
respond	O
,	O
such	O
that	O
β1	O
-	O
expressing	O
monolayers	O
increased	O
process	O
length	O
by	O
1	O
.	O
6	O
-	O
fold	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Fig	O
.	O
5e	O
).	O

A	O
similar	O
result	O
was	O
observed	O
for	O
MCF	O
-	O
7	O
cells	O
,	O
which	O
express	O
endogenous	O
β1	O
(	O
Supporting	O
Information	O
Fig	O
.	O

S4a	O
and	O
S4b	O
).	O

There	O
was	O
no	O
increase	O
in	O
process	O
length	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
over	O
-	O
expressing	O
the	O
Ig	B-GP
domain	O
-	O
deficient	O
mutant	O
β1Δ40	O
–	O
124	O
when	O
grown	O
on	O
β1	O
-	O
expressing	O
monolayers	O
(	O
Fig	O
.	O
5f	O
),	O
suggesting	O
that	O
the	O
adhesion	O
domain	O
is	O
required	O
for	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
.	O

In	O
cerebellar	O
granule	O
neurons	O
,	O
β1	O
-	O
mediated	O
neurite	O
outgrowth	O
requires	O
the	O
presence	O
of	O
Nav1	B-GP
.	I-GP
6	I-GP
and	O
is	O
inhibited	O
by	O
the	O
VGSC	O
pore	O
-	O
blocking	O
toxin	O
TTX	O
.	O
16	O
We	O
found	O
that	O
TTX	O
(	O
30	O
µM	O
)	O
inhibited	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Fig	O
.	O
5h	O
).	O

However	O
,	O
it	O
had	O
no	O
effect	O
on	O
process	O
outgrowth	O
in	O
native	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
,	O
which	O
do	O
not	O
respond	O
to	O
β1	O
-	O
expressing	O
fibroblasts	O
(	O
Fig	O
.	O
5g	O
).	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
β1	O
enhances	O
process	O
outgrowth	O
on	O
BCa	B-DS
cells	O
via	O
trans	O
-	O
homophilic	O
adhesion	O
between	O
β1	O
expressed	O
on	O
the	O
BCa	B-DS
cell	O
,	O
and	O
β1	O
expressed	O
on	O
the	O
adjacent	O
fibroblast	O
,	O
similar	O
to	O
its	O
function	O
in	O
neurons	O
.	O
14	O

β1	O
-	O
mediated	O
process	O
outgrowth	O
requires	O
fyn	B-GP
kinase	I-GP

In	O
neurons	O
,	O
β1	O
increases	O
neurite	O
length	O
via	O
fyn	B-GP
kinase	I-GP
.	O
15	O
CAM	O
-	O
mediated	O
activation	O
of	O
fyn	B-GP
kinase	I-GP
is	O
proposed	O
to	O
initiate	O
the	O
fyn	B-GP
-	O
focal	B-GP
adhesion	I-GP
kinase	I-GP
(	O
FAK	B-GP
)	O
pathway	O
,	O
activating	O
extracellular	B-GP
signal	I-GP
-	I-GP
regulated	I-GP
kinase	I-GP
1	I-GP
/	O
2	O
,	O
leading	O
to	O
neurite	O
outgrowth	O
.	O
38	O
Fyn	B-GP
is	O
upregulated	O
in	O
a	O
number	O
of	O
cancers	B-DS
,	O
where	O
it	O
contributes	O
to	O
an	O
invasive	O
phenotype	O
.	O
39	O
We	O
found	O
that	O
fyn	B-GP
,	O
like	O
β1	O
,	O
was	O
expressed	O
in	O
MCF	O
-	O
10A	O
cells	O
and	O
BCa	B-DS
cell	O
lines	O
(	O
Fig	O
.	O
1g	O
and	O
1h	O
,	O
Supporting	O
Information	O
Fig	O
.	O

S2f	O
).	O

Given	O
that	O
fyn	B-GP
is	O
required	O
for	O
β1	O
-	O
mediated	O
neurite	O
outgrowth	O
,	O
and	O
fyn	B-GP
and	O
β1	O
are	O
coexpressed	O
in	O
brain	O
membranes	O
,	O
15	O
we	O
hypothesized	O
that	O
fyn	B-GP
and	O
β1	O
may	O
colocalize	O
in	O
BCa	B-DS
cells	O
.	O

In	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
,	O
β1	O
was	O
expressed	O
throughout	O
the	O
cytoplasm	O
,	O
on	O
perinuclear	O
internal	O
membranes	O
and	O
lamellipodia	O
(	O
Fig	O
.	O
6a	O
),	O
consistent	O
with	O
previous	O
observations	O
,	O
although	O
the	O
expression	O
of	O
β1	O
was	O
clearly	O
lower	O
in	O
the	O
former	O
.	O
23	O
Importantly	O
,	O
fyn	B-GP
showed	O
a	O
broadly	O
similar	O
distribution	O
to	O
β1	O
,	O
with	O
expression	O
strongest	O
on	O
F	B-GP
-	I-GP
actin	I-GP
-	O
rich	O
lamellipodia	O
.	O

Intensity	O
correlation	O
analysis	O
gave	O
ICQ	O
values	O
>	O
0	O
,	O
indicating	O
that	O
the	O
signals	O
for	O
β1	O
and	O
fyn	B-GP
varied	O
together30	O
(	O
Fig	O
.	O
6b	O
).	O

This	O
result	O
is	O
consistent	O
with	O
β1	O
colocalizing	O
with	O
fyn	B-GP
.	O

A	O
mechanism	O
for	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
and	O
migration	O
in	O
BCa	B-DS
cells	O
.	O

(	O
a	O
)	O
Images	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
.	O

Green	O
:	O
anti	O
-	O
β1	O
for	O
parental	O
MDA	O
-	O
MB	O
-	O
231	O
(	O
with	O
Alexa	O
-	O
488	O
-	O
conjugated	O
secondary	O
antibody	O
)	O
and	O
GFP	B-GP
signal	O
for	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
;	O
red	O
:	O
anti	O
-	O
fyn	B-GP
;	O
magenta	O
:	O
phalloidin	O
to	O
label	O
the	O
actin	B-GP
cytoskeleton	O
;	O
blue	O
:	O
DAPI	O
to	O
label	O
nucleus	O
.	O

White	O
boxes	O
indicate	O
locations	O
of	O
inset	O
zoomed	O
images	O
.	O

Phalloidin	O
is	O
omitted	O
from	O
merged	O
image	O
for	O
clarity	O
.	O

Scale	O
bar	O
,	O
10	O
µm	O
.	O

(	O
b	O
)	O
Intensity	O
correlation	O
-	O
quotients	O
(	O
ICQ	O
)	O
for	O
β1	O
and	O
fyn	B-GP
in	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
(	O
n	O
=	O
20	O
/	O
each	O
).	O

(	O
c	O
)	O
Process	O
length	O
(	O
µm	O
)	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
grown	O
on	O
control	O
or	O
β1	O
-	O
expressing	O
CHL	O
monolayers	O
±	O
5	O
µM	O
PP2	O
(	O
n	O
≥	O
147	O
).	O

(	O
d	O
)	O
Process	O
length	O
(	O
µm	O
)	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
grown	O
on	O
control	O
or	O
β1	O
-	O
expressing	O
CHL	O
monolayers	O
±	O
5	O
µM	O
PP2	O
(	O
n	O
≥	O
223	O
).	O

(	O
e	O
)	O
Process	O
length	O
(	O
µm	O
)	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
grown	O
on	O
control	O
or	O
β1	O
-	O
expressing	O
CHL	O
monolayers	O
±	O
fyn	B-GP
siRNA	O
(	O
n	O
=	O
150	O
).	O

(	O
f	O
)	O
Process	O
length	O
(	O
µm	O
)	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
grown	O
on	O
control	O
or	O
β1	O
-	O
expressing	O
CHL	O
monolayers	O
±	O
fyn	B-GP
siRNA	O
(	O
n	O
=	O
150	O
).	O

(	O
g	O
)	O
A	O
model	O
of	O
possible	O
signalling	O
mechanism	O
underlying	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
in	O
BCa	B-DS
cells	O
.	O
β1	O
from	O
an	O
adjacent	O
fibroblast	O
or	O
cancer	B-DS
cell	O
interacts	O
in	O
trans	O
with	O
β1	O
on	O
the	O
BCa	B-DS
cell	O
,	O
initiating	O
a	O
signaling	O
cascade	O
via	O
fyn	B-GP
kinase	I-GP
,	O
leading	O
to	O
process	O
outgrowth	O
.	O
15	O
Na	O
+	O
conductance	O
through	O
the	O
pore	O
-	O
forming	O
α	O
subunit	O
is	O
also	O
required	O
.	O
16	O
Figure	O
was	O
produced	O
using	O
Science	O
Slides	O
software	O
.	O

Bars	O
are	O
mean	O
+	O
SEM	O
;	O
***	O
p	O
<	O
0	O
.	O
001	O
.	O

We	O
next	O
investigated	O
whether	O
fyn	B-GP
activity	O
is	O
involved	O
in	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
in	O
BCa	B-DS
cells	O
.	O

Inclusion	O
of	O
the	O
src	B-GP
family	I-GP
kinase	I-GP
inhibitor	O
PP2	O
(	O
5	O
µM	O
)	O
in	O
the	O
assay	O
inhibited	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Fig	O
.	O
6d	O
).	O

However	O
,	O
it	O
had	O
no	O
effect	O
on	O
process	O
outgrowth	O
in	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
,	O
which	O
do	O
not	O
respond	O
to	O
β1	O
-	O
expressing	O
fibroblasts	O
(	O
Fig	O
.	O
6c	O
).	O

Importantly	O
,	O
5	O
µM	O
PP2	O
had	O
no	O
effect	O
on	O
cellular	O
viability	O
or	O
proliferation	O
(	O
Supporting	O
Information	O
Figs	O
.	O

S5a	O
and	O
S5b	O
).	O

To	O
establish	O
whether	O
fyn	B-GP
is	O
specifically	O
required	O
for	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
in	O
BCa	B-DS
cells	O
over	O
other	O
members	O
of	O
the	O
src	B-GP
family	O
that	O
are	O
also	O
inhibited	O
by	O
PP2	O
,	O
we	O
next	O
transiently	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
fyn	B-GP
in	O
BCa	B-DS
cells	O
using	O
siRNA	O
,	O
prior	O
to	O
plating	O
on	O
fibroblast	O
monolayers	O
(	O
Supporting	O
Information	O
Fig	O
.	O

S5d	O
).	O

Down	O
-	O
regulation	O
of	O
fyn	B-GP
with	O
siRNA	O
abrogated	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
(	O
p	O
<	O
0	O
.	O
001	O
;	O
Fig	O
.	O
6f	O
).	O

However	O
,	O
there	O
was	O
no	O
effect	O
on	O
baseline	O
process	O
outgrowth	O
in	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
(	O
Fig	O
.	O
6e	O
).	O

PP2	O
and	O
fyn	B-GP
siRNA	O
also	O
inhibited	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
in	O
MCF	O
-	O
7	O
cells	O
(	O
Supporting	O
Information	O
Figs	O
.	O

S4c	O
and	O
S4d	O
).	O

In	O
summary	O
,	O
blocking	O
fyn	B-GP
expression	O
/	O
activity	O
with	O
PP2	O
or	O
siRNA	O
inhibited	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
in	O
BCa	B-DS
cells	O
.	O

These	O
data	O
suggest	O
that	O
fyn	B-GP
is	O
a	O
critical	O
signalling	O
intermediary	O
in	O
the	O
mechanism	O
underlying	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
in	O
BCa	B-DS
cells	O
(	O
Fig	O
.	O
6g	O
),	O
as	O
it	O
is	O
in	O
neurons	O
.	O
15	O

Discussion	O

VGSCs	B-GP
are	O
expressed	O
in	O
cells	O
from	O
a	O
number	O
of	O
different	O
cancers	B-DS
,	O
where	O
they	O
are	O
proposed	O
to	O
play	O
a	O
role	O
in	O
potentiating	O
metastasis	O
.	O
18	O
VGSCs	B-GP
are	O
unique	O
among	O
ion	O
channels	O
in	O
that	O
their	O
“	O
auxiliary	O
”	O
β	O
subunits	O
not	O
only	O
modulate	O
channel	O
activity	O
,	O
but	O
are	O
also	O
CAMs	B-GP
.	O
5	O
Expression	O
of	O
β	O
subunits	O
has	O
been	O
reported	O
in	O
breast	O
,	O
bone	O
,	O
cervical	O
,	O
colorectal	O
,	O
lung	O
,	O
and	O
prostate	B-DS
cancer	I-DS
cell	O
lines	O
,	O
and	O
β1	O
is	O
the	O
dominant	O
isoform	O
in	O
breast	O
,	O
cervical	O
,	O
lung	O
and	O
prostate	B-DS
cancer	I-DS
cell	O
lines	O
(	O
reviewed	O
in	O
Ref	O
.	O
19	O
).	O

However	O
,	O
in	O
vivo	O
evidence	O
for	O
β	O
subunit	O
expression	O
in	O
cancer	B-DS
is	O
limited	O
.	O

We	O
found	O
that	O
β1	O
was	O
up	O
-	O
regulated	O
at	O
mRNA	O
and	O
protein	O
level	O
in	O
BCa	B-DS
specimens	O
compared	O
with	O
non	O
-	O
cancer	B-DS
tissue	O
.	O

Similarly	O
,	O
β1	O
was	O
expressed	O
across	O
a	O
panel	O
of	O
BCa	B-DS
cell	O
lines	O
,	O
although	O
the	O
relative	O
mRNA	O
and	O
protein	O
levels	O
differed	O
.	O

In	O
addition	O
,	O
in	O
tumour	B-DS
specimens	O
,	O
the	O
positive	O
relationship	O
between	O
SCN1B	B-GP
mRNA	O
and	O
ER	O
status	O
was	O
not	O
reflected	O
at	O
the	O
protein	O
level	O
.	O

Discrepancy	O
between	O
mRNA	O
and	O
protein	O
levels	O
has	O
been	O
reported	O
previously	O
for	O
other	O
VGSCs	B-GP
in	O
other	O
tissues	O
.	O
24	O
,	O
40	O
,	O
41	O
Therefore	O
,	O
the	O
relationship	O
between	O
SCN1B	B-GP
mRNA	O
and	O
β1	O
protein	O
levels	O
may	O
be	O
subject	O
to	O
complex	O
regulation	O
,	O
highlighting	O
the	O
critical	O
importance	O
of	O
studying	O
biomarker	O
expression	O
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
.	O

We	O
did	O
not	O
observe	O
a	O
relationship	O
between	O
β1	O
expression	O
and	O
outcome	O
in	O
patient	O
tumour	B-DS
specimens	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
relatively	O
small	O
size	O
of	O
the	O
dataset	O
,	O
and	O
it	O
would	O
be	O
worthwhile	O
in	O
the	O
future	O
to	O
validate	O
the	O
data	O
presented	O
here	O
against	O
larger	O
cohorts	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
show	O
that	O
SCN1B	B-GP
/	O
β1	O
is	O
up	O
-	O
regulated	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
in	O
BCa	B-DS
.	O

We	O
propose	O
that	O
β1	O
warrants	O
further	O
study	O
as	O
a	O
potential	O
biomarker	O
for	O
BCa	B-DS
.	O

β1	O
over	O
-	O
expression	O
increased	O
tumour	B-DS
growth	O
in	O
vivo	O
.	O

Interestingly	O
,	O
this	O
contrasts	O
with	O
the	O
observation	O
that	O
over	O
-	O
expression	O
of	O
β1	O
slightly	O
reduces	O
proliferation	O
in	O
vitro	O
,	O
24	O
suggesting	O
that	O
the	O
tumour	B-DS
microenvironment	O
might	O
be	O
critical	O
to	O
the	O
in	O
vivo	O
tumour	B-DS
-	O
promoting	O
function	O
of	O
β1	O
.	O

In	O
support	O
of	O
this	O
,	O
apoptosis	O
was	O
reduced	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
tumours	B-DS
,	O
which	O
may	O
account	O
for	O
their	O
increased	O
size	O
.	O

Cell	O
adhesion	O
can	O
promote	O
apoptosis	O
suppression	O
in	O
cancer	B-DS
cells	O
via	O
FAK	B-GP
activation42	O
and	O
further	O
work	O
is	O
required	O
to	O
establish	O
whether	O
or	O
not	O
β1	O
-	O
dependent	O
adhesion	O
promotes	O
tumour	B-DS
cell	O
survival	O
.	O

There	O
was	O
increased	O
density	O
of	O
vascular	O
structures	O
in	O
the	O
β1	O
over	O
-	O
expressing	O
tumours	B-DS
,	O
and	O
VEGF	B-GP
secretion	O
was	O
increased	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
in	O
vitro	O
,	O
suggesting	O
that	O
β1	O
may	O
enhance	O
angiogenesis	O
.	O

Several	O
classes	O
of	O
CAMs	B-GP
are	O
known	O
to	O
promote	O
angiogenesis	O
,	O
including	O
integrins	B-GP
,	O
cadherins	B-GP
,	O
and	O
immunoglobulin	B-GP
superfamily	O
CAMs	B-GP
,	O
43	O
raising	O
the	O
possibility	O
that	O
β1	O
may	O
contribute	O
to	O
promoting	O
blood	O
vessel	O
development	O
through	O
heterophilic	O
adhesion	O
.	O

Interestingly	O
,	O
over	O
-	O
expression	O
of	O
β2	O
in	O
prostate	B-DS
cancer	I-DS
cells	O
has	O
the	O
reverse	O
effect	O
,	O
reducing	O
tumour	B-DS
growth	O
.	O
44	O
Despite	O
its	O
structural	O
similarity	O
to	O
β1	O
,	O
β2	O
appears	O
to	O
play	O
a	O
different	O
role	O
in	O
the	O
CNS	O
,	O
and	O
is	O
not	O
essential	O
for	O
postnatal	O
development	O
.	O
5	O
Thus	O
,	O
as	O
in	O
the	O
CNS	O
,	O
different	O
β	O
subunits	O
may	O
perform	O
distinct	O
functions	O
in	O
different	O
cancer	B-DS
microenvironments	O
.	O

β1	O
is	O
a	O
multifunctional	O
molecule	O
that	O
plays	O
a	O
critical	O
role	O
during	O
CNS	O
development	O
.	O
5	O
Although	O
β1	O
is	O
essential	O
for	O
regulating	O
excitability	O
through	O
fine	O
-	O
tuning	O
VGSC	O
gating	O
and	O
kinetics	O
,	O
16	O
its	O
function	O
as	O
a	O
CAM	O
is	O
required	O
for	O
neurite	O
outgrowth	O
,	O
migration	O
,	O
fasciculation	O
and	O
synaptic	O
connectivity	O
.	O
15	O
–	O
17	O
In	O
fact	O
,	O
β1	O
may	O
function	O
as	O
a	O
CAM	O
,	O
independent	O
of	O
channel	O
activity	O
under	O
certain	O
conditions	O
.	O
5	O
Other	O
CAMs	B-GP
that	O
regulate	O
neuronal	O
migration	O
and	O
pathfinding	O
have	O
been	O
reported	O
in	O
tumours	B-DS
,	O
where	O
they	O
play	O
a	O
pathological	O
role	O
and	O
associate	O
with	O
poor	O
prognosis	O
.	O
45	O
It	O
is	O
therefore	O
not	O
unreasonable	O
to	O
expect	O
that	O
β1	O
may	O
do	O
the	O
same	O
.	O

We	O
showed	O
previously	O
that	O
β1	O
enhances	O
cell	O
-	O
cell	O
adhesion	O
and	O
cell	O
-	O
substrate	O
adhesion	O
in	O
BCa	B-DS
cells	O
in	O
vitro	O
.	O
24	O
In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
β1	O
over	O
-	O
expression	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
caused	O
a	O
more	O
elongate	O
cellular	O
morphology	O
within	O
tumours	B-DS
,	O
and	O
enhanced	O
process	O
outgrowth	O
in	O
vitro	O
via	O
trans	O
-	O
homophilic	O
adhesion	O
.	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
did	O
not	O
occur	O
in	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
,	O
which	O
express	O
a	O
low	O
level	O
of	O
endogenous	O
β1	O
.	O

The	O
latter	O
result	O
suggests	O
that	O
β1	O
expression	O
on	O
the	O
tumour	B-DS
cell	O
may	O
need	O
to	O
be	O
above	O
a	O
threshold	O
in	O
order	O
to	O
induce	O
process	O
outgrowth	O
and	O
enhance	O
tumour	B-DS
growth	O
and	O
metastasis	O
.	O

We	O
found	O
that	O
,	O
as	O
in	O
neurons	O
,	O
15	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
in	O
BCa	B-DS
cells	O
required	O
fyn	B-GP
kinase	I-GP
.	O
β1	O
-	O
mediated	O
neurite	O
outgrowth	O
in	O
neurons	O
is	O
also	O
activity	O
-	O
dependent	O
.	O
16	O
Interestingly	O
,	O
Na	O
+	O
current	O
promotes	O
src	B-GP
family	I-GP
kinase	I-GP
activity	O
and	O
pro	O
-	O
invasive	O
morphology	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
,	O
46	O
which	O
fits	O
with	O
other	O
data	O
showing	O
that	O
α	O
subunits	O
potentiate	O
the	O
invasiveness	O
of	O
BCa	B-DS
cells	O
.	O
20	O
–	O
22	O
,	O
46	O
,	O
47	O
We	O
found	O
that	O
TTX	O
inhibited	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
,	O
suggesting	O
that	O
,	O
as	O
in	O
neurons	O
,	O
16	O
α	O
subunit	O
function	O
is	O
required	O
(	O
Fig	O
.	O
6g	O
).	O

Thus	O
,	O
Nav1	B-GP
.	I-GP
5	I-GP
and	O
β1	O
may	O
both	O
promote	O
mesenchymal	O
-	O
like	O
elongate	O
morphology	O
in	O
BCa	B-DS
cells	O
,	O
via	O
a	O
combination	O
of	O
Na	O
+	O
current	O
and	O
adhesion	O
.	O

Our	O
data	O
suggest	O
that	O
β1	O
can	O
enhance	O
tumour	B-DS
growth	O
and	O
metastasis	O
via	O
a	O
trans	O
-	O
homophilic	O
adhesion	O
mechanism	O
that	O
enhances	O
process	O
outgrowth	O
on	O
metastatic	O
tumour	B-DS
cells	O
,	O
enabling	O
their	O
dissemination	O
from	O
the	O
primary	O
tumour	B-DS
and	O
into	O
surrounding	O
tissues	O
.	O

This	O
would	O
fit	O
with	O
the	O
observation	O
that	O
outgrowth	O
of	O
processes	O
,	O
e	O
.	O
g	O
.,	O
pseudopodia	O
,	O
from	O
cancer	B-DS
cells	O
increases	O
motility	O
,	O
invasion	O
,	O
and	O
metastasis	O
.	O
35	O
–	O
37	O
Thus	O
,	O
β1	O
may	O
be	O
involved	O
in	O
collective	O
cell	O
migration	O
and	O
invasion	O
during	O
tumour	B-DS
spreading	O
,	O
48	O
,	O
49	O
similar	O
to	O
its	O
role	O
in	O
pathfinding	O
and	O
fasciculation	O
during	O
CNS	O
development	O
.	O
15	O
,	O
17	O
However	O
,	O
we	O
do	O
not	O
yet	O
know	O
whether	O
β1	O
interactions	O
in	O
trans	O
occur	O
between	O
adjacent	O
tumour	B-DS
cells	O
,	O
or	O
between	O
tumour	B-DS
cells	O
and	O
stromal	O
cells	O
,	O
or	O
both	O
.	O

Further	O
complexity	O
is	O
added	O
by	O
the	O
possibility	O
that	O
β1	O
may	O
interact	O
heterophilically	O
with	O
other	O
CAMs	B-GP
,	O
9	O
–	O
12	O
and	O
/	O
or	O
extracellular	B-GP
matrix	I-GP
proteins13	I-GP
present	O
in	O
the	O
tumour	B-DS
microenvironment	O
,	O
dependent	O
on	O
cell	O
types	O
/	O
status	O
within	O
the	O
tumour	B-DS
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
that	O
SCN1B	B-GP
/	O
β1	O
recapitulates	O
its	O
neurodevelopmental	O
role	O
to	O
promote	O
breast	B-DS
tumour	I-DS
growth	O
and	O
metastasis	O
.	O

This	O
fits	O
with	O
a	O
growing	O
body	O
of	O
evidence	O
implicating	O
VGSCs	B-GP
as	O
mediators	O
of	O
an	O
invasive	O
/	O
metastatic	O
phenotype	O
.	O
19	O
Up	O
-	O
regulation	O
of	O
genes	O
,	O
e	O
.	O
g	O
.	O
SCN1B	B-GP
,	O
required	O
for	O
normal	O
migration	O
and	O
invasion	O
processes	O
during	O
development	O
,	O
may	O
represent	O
a	O
critical	O
event	O
in	O
the	O
progression	O
towards	O
metastasis	O
.	O
50	O
We	O
therefore	O
propose	O
that	O
(	O
i	O
)	O
β1	O
may	O
represent	O
a	O
novel	O
biomarker	O
during	O
disease	O
development	O
,	O
and	O
(	O
ii	O
)	O
targeting	O
β1	O
-	O
mediated	O
adhesion	O
interactions	O
may	O
have	O
potential	O
as	O
novel	O
anti	O
-	O
cancer	B-DS
therapy	O
.	O

Supplementary	O
Information	O
Figure	O
1	O
.	O
SCN1B	B-GP
mRNA	O
expression	O
in	O
breast	B-DS
cancer	I-DS
.	O

(	O
A	O
)	O
SCN1B	B-GP
expression	O
profile	O
in	O
the	O
Lu	O
Breast	O
dataset	O
,	O
segregated	O
by	O
ER	O
status	O
(	O
n	O
=	O
129	O
).	O

(	O
B	O
)	O
SCN1B	B-GP
expression	O
vs	O
.	O
ESR1	B-GP
expression	O
in	O
the	O
Lu	O
Breast	O
dataset	O
.	O

(	O
C	O
)	O
SCN1B	B-GP
expression	O
in	O
the	O
context	O
of	O
genomic	O
neighbours	O
.	O

Genes	O
are	O
sorted	O
by	O
their	O
genomic	O
distance	O
to	O
SCN1B	B-GP
(	O
indicated	O
underneath	O
matrix	O
).	O

Colours	O
indicate	O
mean	O
fold	O
change	O
in	O
expression	O
(	O
from	O
0	O
.	O
65	O
-	O
1	O
.	O
8	O
)	O
in	O
ER	O
+	O
cases	O
relative	O
to	O
ER	O
-	O
cases	O
across	O
five	O
Oncomine	O
datasets	O
.	O

(	O
D	O
)	O
β1	O
and	O
(	O
E	O
)	O
β1B	O
mRNA	O
expression	O
across	O
a	O
panel	O
of	O
BCa	O
cell	O
lines	O
(	O
qPCR	O
relative	O
to	O
GAPDH	O
,	O
calibrator	O
=	O
SKBR3	O
;	O
n	O
=	O
3	O
).	O

(	O
F	O
)	O
Expression	O
of	O
β1	O
,	O
β1B	O
,	O
and	O
GREB1	O
(	O
relative	O
to	O
GAPDH	O
)	O
in	O
MCF	O
-	O
7	O
cells	O
treated	O
with	O
vehicle	O
,	O
or	O
10nM	O
estradiol	O
and	O
/	O
or	O
1μM	O
fulvestrant	O
(	O
n	O
=	O
3	O
).	O

Estradiol	O
significantly	O
increased	O
mRNA	O
level	O
(	O
reversed	O
by	O
fulvestrant	O
)	O
of	O
the	O
positive	O
control	O
,	O
GREB1	O
,	O
an	O
estrogen	O
-	O
regulated	O
gene	O
.	O

Box	O
plot	O
dots	O
,	O
maximum	O
and	O
minimum	O
values	O
;	O
whiskers	O
,	O
90th	O
and	O
10th	O
percentile	O
values	O
;	O
and	O
horizontal	O
lines	O
,	O
75th	O
,	O
50th	O
,	O
and	O
25th	O
percentile	O
values	O
.	O
**	O
P	O
<	O
0	O
.	O
01	O
;	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O

Supplementary	O
Information	O
Figure	O
2	O
.	O
β1	O
,	O
fyn	O
,	O
CD44	O
and	O
E	O
-	O
cadherin	O
protein	O
levels	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

(	O
A	O
)	O
Western	O
blot	O
of	O
β1	O
in	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
(	O
expressing	O
eGFP	O
)	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
(	O
overexpressing	O
β1	O
-	O
eGFP	O
C	O
-	O
terminal	O
fusion	O
,	O
67	O
kDa	O
).	O

(	O
B	O
)	O
Protein	O
levels	O
of	O
β1	O
and	O
β1	O
-	O
GFP	O
,	O
relative	O
to	O
?-	O
tubulin	O
(	O
n	O
=	O
3	O
repeats	O
).	O

Bars	O
are	O
mean	O
+	O
SEM	O
.	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O

(	O
C	O
)	O
Images	O
of	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
labelled	O
with	O
anti	O
-	O
CD44	O
and	O
anti	O
-	O
E	O
-	O
cadherin	O
antibodies	O
(	O
red	O
),	O
and	O
DAPI	O
to	O
label	O
the	O
nucleus	O
.	O

Positive	O
control	O
for	O
E	O
-	O
cadherin	O
labelling	O
,	O
MCF	O
-	O
7	O
cells	O
.	O

Scale	O
bar	O
,	O
50μm	O
.	O

(	O
D	O
)	O
Western	O
blot	O
of	O
CD44	O
in	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
.	O

(	O
E	O
)	O
Western	O
blot	O
of	O
E	O
-	O
cadherin	O
in	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
.	O

Positive	O
control	O
=	O
MCF	O
-	O
7	O
cells	O
.	O

(	O
F	O
)	O
Western	O
blot	O
of	O
fyn	O
kinase	O
in	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
.	O

Supplementary	O
Information	O
Figure	O
3	O
.	O

Luciferase	O
and	O
GFP	O
expression	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

(	O
A	O
)	O
Representative	O
bioluminescent	O
image	O
of	O
luciferase	O
activity	O
in	O
cultured	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
(	O
1x105	O
cells	O
/	O
well	O
),	O
10	O
min	O
following	O
addition	O
of	O
D	O
-	O
luciferin	O
(	O
1	O
mg	O
/	O
ml	O
).	O

(	O
B	O
)	O
Bioluminescence	O
measured	O
from	O
cultured	O
cells	O
(	O
n	O
=	O
6	O
wells	O
/	O
group	O
).	O

(	O
C	O
)	O
Images	O
showing	O
eGFP	O
expression	O
(	O
green	O
)	O
in	O
control	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
counterstained	O
with	O
DAPI	O
(	O
blue	O
).	O

Scale	O
bar	O
,	O
50μm	O
.	O

(	O
D	O
)	O
Quantification	O
of	O
eGFP	O
signal	O
intensity	O
per	O
cell	O
(	O
n	O
=	O
50	O
).	O

Individual	O
cells	O
were	O
delineated	O
using	O
the	O
freeform	O
line	O
tool	O
in	O
ImageJ	O
in	O
order	O
to	O
obtain	O
a	O
pixel	O
intensity	O
score	O
per	O
cell	O
.	O

(	O
E	O
)	O
Metastasis	O
in	O
lung	O
section	O
from	O
a	O
β1	O
tumour	O
-	O
bearing	O
mouse	O
showing	O
GFP	O
expression	O
(	O
green	O
)	O
in	O
tumour	O
cells	O
overlaying	O
with	O
human	O
nuclear	O
antigen	O
(	O
HNA	O
)	O
expression	O
(	O
red	O
),	O
counterstained	O
with	O
DAPI	O
(	O
blue	O
).	O

White	O
dashed	O
lines	O
delineate	O
extent	O
of	O
metastasis	O
.	O

Scale	O
bar	O
,	O
100μm	O
.	O

Data	O
are	O
mean	O
+	O
SEM	O
.	O

Supplementary	O
Information	O
Figure	O
4	O
.	O
β1	O
-	O
mediated	O
process	O
outgrowth	O
in	O
MCF	O
-	O
7	O
cells	O
.	O

(	O
A	O
)	O
Typical	O
images	O
of	O
MCF	O
-	O
7	O
cells	O
grown	O
on	O
control	O
or	O
β1	O
-	O
expressing	O
CHL	O
fibroblast	O
monolayers	O
.	O

MCF	O
-	O
7	O
cells	O
were	O
visualised	O
by	O
staining	O
with	O
anti	O
-	O
cytokeratin	O
18	O
antibody	O
(	O
red	O
).	O

Scale	O
bar	O
,	O
20μm	O
.	O

(	O
B	O
)	O
Process	O
length	O
(	O
μm	O
)	O
of	O
MCF	O
-	O
7	O
cells	O
grown	O
on	O
control	O
or	O
β1	O
-	O
expressing	O
CHL	O
monolayers	O
(	O
n	O
=	O
300	O
).	O

(	O
C	O
)	O
Process	O
length	O
(	O
μm	O
)	O
of	O
MCF	O
-	O
7	O
cells	O
grown	O
on	O
control	O
or	O
β1	O
-	O
expressing	O
CHL	O
monolayers	O
±	O
5μM	O
PP2	O
(	O
n	O
=	O
180	O
).	O

(	O
D	O
)	O
Process	O
length	O
(	O
μm	O
)	O
of	O
MCF	O
-	O
7	O
cells	O
grown	O
on	O
control	O
or	O
β1	O
-	O
expressing	O
CHL	O
monolayers	O
±	O
fyn	O
siRNA	O
(	O
n	O
=	O
150	O
).	O

Bars	O
are	O
mean	O
+	O
SEM	O
;	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O

Supplementary	O
Information	O
Figure	O
5	O
.	O

Targeting	O
fyn	O
expression	O
/	O
activity	O
.	O

(	O
A	O
)	O
Viability	O
(%)	O
of	O
MCF	O
-	O
7	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
following	O
treatment	O
with	O
PP2	O
(	O
0	O
.	O
5	O
,	O
1	O
,	O
5	O
,	O
10	O
,	O
30μM	O
)	O
or	O
vehicle	O
for	O
24h	O
,	O
normalised	O
to	O
control	O
(	O
n	O
=	O
60	O
).	O

(	O
B	O
)	O
Proliferation	O
of	O
MCF	O
-	O
7	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
following	O
treatment	O
with	O
PP2	O
(	O
0	O
.	O
5	O
,	O
1	O
,	O
5	O
,	O
10	O
,	O
30μM	O
)	O
or	O
vehicle	O
for	O
24h	O
,	O
normalised	O
to	O
control	O
(	O
n	O
=	O
9	O
).	O

(	O
C	O
)	O
GAPDH	O
mRNA	O
expression	O
in	O
MCF	O
-	O
7	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
following	O
transfection	O
with	O
non	O
-	O
targeting	O
control	O
siRNA	O
(“	O
Control	O
”)	O
or	O
siRNA	O
targeting	O
GAPDH	O
(“	O
siRNA	O
”).	O

QPCR	O
relative	O
to	O
β	O
-	O
actin	O
(	O
n	O
=	O
3	O
).	O

In	O
both	O
cell	O
lines	O
,	O
down	O
-	O
regulation	O
of	O
GAPDH	O
expression	O
with	O
siRNA	O
indicated	O
transfection	O
efficiency	O
≥	O
90	O
%.	O

(	O
D	O
)	O
Fyn	O
mRNA	O
expression	O
in	O
MCF	O
-	O
7	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
β1	O
cells	O
following	O
transfection	O
with	O
non	O
-	O
targeting	O
control	O
siRNA	O
(“	O
Control	O
”)	O
or	O
siRNA	O
targeting	O
fyn	O
kinase	O
(“	O
siRNA	O
”).	O

QPCR	O
relative	O
to	O
GAPDH	O
(	O
n	O
=	O
3	O
repeat	O
transfections	O
).	O

Data	O
are	O
mean	O
±	O
SEM	O
;	O
***	O
P	O
<	O
0	O
.	O
001	O
.	O

Supplementary	O
Information	O
Table	O
1	O
.	O

Primer	O
sequences	O
.	O

Supplementary	O
Information	O
Table	O
2	O
.	O

Correlation	O
between	O
SCN1B	O
expression	O
and	O
histoclinical	O
characteristics	O

Supplementary	O
Information	O
Table	O
3	O
.	O

Patient	O
histoclinical	O
characteristics	O
and	O
β1	O
expression	O
.	O

Supplementary	O
Information	O

